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We exist as opposed to 
a customary state of not being 
in this world of breathtaking exceptions. 
 
-AW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family 
 
 
 
ABSTRACT 
 
Background: Celiac disease (CD) is an autoimmune disorder occurring worldwide 
with a prevalence of about 1% of the Western population. The classic presentation 
comprises symptoms of malabsorption such as diarrhea and weight loss, but the 
spectrum of symptoms is wide, including asymptomatic disease. CD is induced by 
dietary gluten in genetically susceptible individuals. The pathogenesis of CD has not 
been fully elucidated, and although environmental factors such as infant feeding 
practice and infectious disease have been suggested, results are inconclusive. Treatment 
of CD consists of a life-long gluten-free diet (GFD). Individuals with CD suffer 
increased risk of a number of comorbid conditions, including diabetes mellitus type 1, 
depression and certain malignancies.  
 
Aims: The aim of this thesis was to investigate the risk of venous thromboembolism 
(VTE), end-stage renal disease (ESRD), and IgA nephropathy (IgAN) in individuals 
with CD. These studies were carried out with the objective to obtain increased 
knowledge regarding CD characteristics, in order to optimally design the care of 
individuals with CD and identify possible groups with increased risk of CD. A separate 
aim of this thesis was to further investigate the pathogenesis of CD, by assessing the 
effect of infectious disease at time of gluten introduction in infants on the risk of future 
CD.  
 
Materials and methods: The risk of VTE was assessed in a cohort of 14,207 
individuals with a discharge diagnosis of CD recorded in the Swedish hospital 
discharge register. When investigating renal complications (ESRD and IgAN), studies 
were based on a CD cohort identified through Swedish biopsy registers (about 29,000 
individuals). Reference individuals, matched for age, sex, calendar period and county, 
were selected (five per index individual with CD) from the Swedish total population 
register. Cox regression was used to investigate the associations between CD and 
outcome data in these population-based cohort studies.  
We used the All Babies in Southeast Sweden (ABIS) population-based cohort study, 
where the parents of all children born in 1997-1999 in the area were invited to 
participate. Parents of 9,849 children prospectively completed a diary with feeding data 
and parent-reported infections during the child’s first year of life. The pediatric 
departments in the area reported children diagnosed with CD. Cox regression was used 
to assess the risk of CD in children with infection at time of gluten introduction.  
 
Results: Among individuals with a discharge diagnosis of CD, 406 (2.6%) suffered 
subsequent VTE, compared with 1105/76,910 (1.4%) of reference individuals, 
corresponding to a modestly increased risk of VTE in CD (Hazard ratio, HR, 1.86; 95% 
Confidence interval, CI, 1.54-2.24). This risk increase was limited to individuals 
diagnosed with CD in adulthood. Individuals with biopsy-verified CD suffered a three-
fold increased risk of future ESRD (HR, 2.87; 95% CI 2.22-3.71). The estimate 
remained significant in analyses where we adjusted for the presence of type 1 diabetes 
mellitus, and after restricting the outcome to ESRD recorded in the Swedish patient 
register and in the Swedish renal register. Individuals with biopsy-verified CD also 
suffered increased risk of future biopsy-verified IgAN (HR, 3.03; 95% CI 1.22-7.56).  
This risk increase was only seen in men with CD.  
 
Although parent-reported infections were more common among children with CD 
(p=0.035), we found no increased risk of CD among children with any reported 
infection (HR, 1.8; 95% CI 0.9-3.6) or gastroenteritis (HR, 2.6; 95% CI 0.2-30.8) at 
time of gluten introduction (analyses adjusted for age at gluten introduction, age at end 
of breastfeeding, and age at any infection). The majority of Swedish children were 
breastfed for more than 9 months.  
 
Conclusions: CD is modestly associated with future VTE, likely due to a combination 
of chronic inflammation and surveillance bias. CD is a risk factor for future ESRD and 
IgAN. Although absolute risks are low, our findings warrant increased awareness 
regarding renal function in the care of individuals with CD. Future studies should 
evaluate the effect of adherence to a gluten-free diet and risk of future renal disease to 
potentially identify individuals at risk.  
 
Infection at time of gluten introduction does not seem to be a major risk factor for 
future CD. In a setting where adherence to infant feeding guidelines is high, duration of 
breastfeeding and age at gluten introduction are no major risk factors for CD. Future 
studies should include longer follow-up to assess long-term effects of environmental 
factors during the first year of life.   
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1 INTRODUCTION 
Celiac disease (CD) is a common chronic disorder, affecting some 1% of the 
population in the Western world1. In individuals with CD, ingestion of the storage 
proteins of wheat, barley and rye (collectively termed gluten) activate the innate and 
adaptive immune system. This results in a characteristic inflammation of the small 
intestine, with atrophy of the small intestinal villi and production of disease-specific 
antibodies. Intestinal healing is achieved upon treatment with a gluten-free diet (GFD).  
 
Although the expression of human leukocyte antigen (HLA) DQ2 or DQ8 is required 
for CD pathogenesis2, these genotypes are common in the general population3 and do 
not provide an understanding of why some individuals develop CD and others do not. 
CD pathogenesis is considered multifactorial, likely dependent on an interplay of 
genetic and environmental factors such as infant feeding practice4 and infections5.  
 
The classic presentation of CD includes symptoms of malabsorption such as weight-
loss, diarrhea, and growth retardation in children6. Although initially considered a 
largely pediatric gastro-intestinal disorder, the observations that CD may develop at any 
age, may present with symptoms from other organ systems, or may be asymptomatic 
has led to a changed view. CD is currently considered a multisystemic disorder that 
should be considered in all age groups6. Individuals with CD suffer increased risk of a 
number of comorbid conditions, including autoimmune and non-autoimmune disorders 
such as depression, certain malignancies, and diabetes mellitus type 11.  
 
The aim of this thesis was to examine the risk of venous thromboembolism or renal 
disease in CD, in order to shed further light on the burden of disease in CD and to 
possibly identify groups at high risk for CD where screening may be warranted. 
Another aim was to investigate the effect of potential environmental CD risk factors 
during the first year of life, to improve our understanding of CD pathogenesis and, if 
possible, suggest future preventive measures.  
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2 BACKGROUND 
2.1 A BRIEF HISTORY OF CELIAC DISEASE 
In the second century AD, Aretaus the Cappadocian described a malabsorptive 
syndrome with chronic diarrhea, dubbing it the “celiac state” after the Greek 
“koiliakos” (abdomen)7. Dr Samuel Gee, an English physician, honored the Greek 
wording when he, in 1888, published his monograph on the celiac affection; a vivid 
description of chronic indigestion found in all ages. Gee deduced that “if the patient can 
be cured at all, it must be by means of diet”8. A diet consisting of ripe bananas and rice 
as the only sources of carbohydrates was advocated to those affected by the syndrome. 
 
Identification of gluten as the dietetic offender was achieved by Dutch physician W.K. 
Dicke, who noted that children with CD improved dramatically during the Second 
World War. At this time, staples such as wheat, rye, and barley were scarce. Contra-
intuitively, a negative effect on the health of these children was seen when famine was 
relieved and the grains were re-introduced to the diet; an observation leading to the 
invention of the gluten-free diet9.   
 
 
2.2 DESCRIPTIVE EPIDEMIOLOGY 
2.2.1 Prevalence in non-selected populations 
Historically CD has been considered a rare disorder. With the evolution of modern 
diagnostic tools, this view has changed. CD is now generally regarded as a common 
chronic disorder affecting children and adults worldwide. The prevalence is generally 
cited as about 1% of the Western population10, but figures vary according to age, year 
of measurement and how CD is defined (histopathologic criteria and/or serology)11.  An 
overview of estimates obtained through screening studies in unselected populations is 
presented in Table 1.  
 
CD occurs worldwide. The highest prevalence reported is among the Saharawi childen 
in Algeria, where serology screening revealed a prevalence of 5.6%22. In Egypt, a more 
moderate prevalence among children was reported (0.5%)23. Screening studies in South 
America showed a high prevalence of CD in Mexico (2.7%), but lower in Brazil and 
Argentina (0.1%, 0.6% respectively), although the definitions of CD varied (Table 1) 
25.26. Few screening studies have been performed in Asia. Sood et al reported a 0.3% 
prevalence of biopsy-verified CD in Indian school-children, however the prevalence 
was likely underestimated since screening was restricted to children with GI 
symptoms(Table 1) 27.  
 
The prevalence of CD has increased over time. Part of this increase is likely due to an 
increased use of serological test and the inclusion of cases with only minor mucosal 
lesions in the presence of positive serology. However, several studies have investigated 
prevalence in different time periods, suggesting a true increase in prevalence over time 
that does not depend on changes in clinical practice17-19. This is coherent with reports of 
increased prevalence over time in another immune-mediated disease (diabetes mellitus 
type 1) 28.   
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Table 1. CD prevalence reported by screening studies. 
 
Region and author  Inclusion criteria  Age group  Prevalence 
North America       Fasano (2003)12  tTG and VA or EMA + HLA‐DQ2/DQ8  All ages  0.8% Hill (2000)13  VA    0.5‐20 years  1.8% 
Europe       Vilppula (2009)14  VA  >55  2.3% Walker (2010)15  VA  VA +/‐ IEL>25/100 and positive serology 
Adults  0.7%  1.8% Myleus (2009)16  tTG and VA or IEL>30 + symptoms  12 year olds   2.9% Lohi (2007)17  EMA or previous clinical CD 
1978­1980 
2000­2001 (two separate 
samples) 
Adults    1.0% 2.0% Rubio‐Tapia (2009)18  EMA+tTG positivity 
1948­1954 
2006­2008 (historical vs 
modern cohort, matched for 
age at sampling) 
Young adults     0.2% 0.9% Catassi (2010)19  EMA+tTG positivity 
1974 
1989 (same cohort, repeated 
measurements) 
Adults    0.2% 0.5% Mustalahti (2010)20  Previously diagnosed or tTG+EMA positive  Adults   1.0% 
Asia/Pacific       Cook (2000)21  EMA + VA  Adults  1.2% 
Africa       Catassi (1999)22  EMA  1.5‐14 yrs  5.6% Abu‐Zekry (2008)23  Positive serology + biopsy with Marsh stage I‐III.   7 months‐ 18 years  0.5% 
Latin and South America       Remes‐Troche (2006)24  tTG   Adults  2.7% Gandolfi (2000)25  VA  Adults  0.1% Gomez (2001)26  EMA and/or VA  16‐79 years  0.6% 
Asia       Sood (2006)27  VA  3‐17 years  0.3% 
Abbreviations: EMA, endomysial antibody; IEL, intraepithelial lymphocytes; tTG, 
tissue transglutaminase antibody; VA, villous atrophy.   
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2.2.2 Prevalence in selected populations 
2.2.2.1 Gender and relatives 
 
As is the case in several other autoimmune disorders29, there is an asymmetric gender 
distribution of CD prevalence. CD is two to three times more common in women than 
in men30.  
 
An increased risk of CD has been observed in relatives to individuals with CD. Fasano 
et al reported increased prevalence among first- and second-degree relatives to 
individuals with biopsy-verified CD (4.5% and 2.6% respectively) compared with not-
at-risk individuals (0.8%), but a positive serology and genetic test sufficed to establish a 
CD diagnosis in relatives12. Another study found a CD prevalence of 10% among 
screened first-degree relatives (small-intestinal biopsy Marsh stage II-III required for 
CD diagnosis)31.  
 
2.2.2.2 Type 1 diabetes mellitus and autoimmune thyroiditis 
 
Individuals with type 1 diabetes mellitus (T1DM) suffer increased risk of CD32, with a 
reported prevalence of 2-5% in the T1DM population12, 32, 33. Some studies report even 
higher estimates of CD prevalence in T1DM, for example 12.3% in a Danish study34. In 
the majority of patients, CD is preceded by T1DM35, however one study from our 
group found increased risk of future T1DM among individuals with prior CD 
(prevalence 1.0%, HR, 2.4; 95% CI 1.9-3.0)36. The reasons behind the association 
between T1DM and CD include shared genetic susceptibility at the human leukocyte 
antigen (HLA) level37 and in non-HLA regions38, as well as common environmental 
risk-factors such as infant feeding pattern39. There is no increased risk of diabetes 
mellitus type 2 among individuals with CD40. 
 
Studies have reported an increased prevalence of CD among individuals with 
autoimmune thyroid disorders41, 42, with one study reporting hazard ratios from 2.0 to 
4.0 for future thyroid disease (hyper-, hypothyroidism, and thyroiditis) in individuals 
with CD43.  
 
2.2.2.3 Turner and Down’s syndromes 
 
Increased CD and thyroid autoantibodies have been detected in Turner syndrome44. The 
prevalence of CD among individuals with Turner syndrome has been reported 
increased (6.4%)45. In Down’s syndrome, CD prevalence is estimated at 5-19% 46-48. 
CD screening by means of serology is indicated in individuals with Down’s syndrome 
due to the high prevalence of CD in this group, and the often-prolonged patient’s delay.  
 
2.2.2.4 Symptoms 
 
Individuals with CD may seek medical advice due to abdominal bloating and pain 
without signs of malabsorption. This clinical presentation is indistinguishable from that 
of irritable bowel syndrome (IBS). In a screening study, individuals newly diagnosed 
with IBS according to the Rome II criteria were at a seven-fold increased risk of having 
CD, with a CD prevalence of 5% in the IBS population49. A later meta-analysis 
described a four-fold increased risk of CD among individuals with IBS50.  
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Symptoms and signs other than GI symptoms may be indicative of increased risk of 
CD. In a primary care case-finding study, the most common clinical presentation of CD 
was anemia, noted in 50% of cases51. Most studies show a prevalence of biopsy-
verified CD of about 5% in individuals with iron-deficiency anemia52-54. Additionally, 
low 25-(OH) D-vitamin has been reported to be present in more than 50% of patients 
with CD55.  
 
2.2.2.5 Concluding remarks regarding selected populations 
 
Screening for CD in at-risk populations described above seems reasonable given the 
elevated risk of CD described in previous studies. Indeed, in children with Down’s 
syndrome, T1DM, family members, and in individuals with autoimmune thyroid 
disorder, this is common practice56. For the other at-risk groups mentioned above, 
screening by CD serology has been suggested11.  
 
2.2.3 Incidence 
Murray et al reported an overall annual incidence of 2.1 per 100,000 person-years 
based on a study of diagnosed CD in Olmsted county residents from 1950-200157. 
Interestingly, incidence rates increased over time, starting at 0.9 per 100,000 person-
years in 1950-1989, to 3.3 per 100,000 person-years during the 1990’s and 9.1 per 
100,000 person-years in the last two years of the study. A higher annual incidence of 75 
per 100,000 person-years was reported in a Finnish study, based on a screening study 
of individuals over 55 years of age in 2002-200514. Lastly, a Swedish study 
investigated the incidence of clinically detected CD over time in children under 2 years 
of age. A rate of 50-60 cases per 100,000 person-years was seen, with a temporary 
four-fold increase during “the Swedish epidemic” 1985-1987 (see section 2.3.4.1)58. 
 
 
2.3 PATHOGENESIS 
2.3.1 Genetics 
Genetics play a key role in the development of CD. Studies have found increased 
prevalence of CD in first- and second degree relatives to individuals with CD12, 31. 
Additionally, a concordance rate of 75% has been found among monozygotic twins59.  
 
CD is considered a multigenetic disorder. The dominant susceptibility locus for CD is 
the human leukocyte antigen (HLA)60, proteins encoded by HLA genes in the major 
histocompatibility complex on chromosome 6. Individuals with CD are HLA 
DQA1*05-DQB1*02 (DQ2) and DQA1*03-DQB1*0302 (DQ8) positive61. However, 
since about one third of the Western population carry these alleles62, and only a fraction 
of these individuals develop CD, it can be concluded that these genes are required but 
alone not a sufficient cause of the disorder. HLA-DQ2/DQ8 positivity has been 
estimated to contribute approximately 40% of the genetic load in CD63.  
 
Recent genome-wide association studies have shed light on non-HLA genes involved 
in the pathogenesis of CD. It seems there are a great number of different genes involved 
(to date >100)64, each contributing a very small portion of the risk but together 
constituting 60% of the total genetic load in CD65.  Many of these genes are immune-
related, and have been associated with other autoimmune disorders65. 
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2.3.2 Gluten- sine qua non 
Gluten is the collective name given to the storage proteins (prolamines) of wheat, 
barley and rye. In wheat, these proteins consist of an alcohol-soluble part (gliadin) and 
a water-soluble part (glutenin). In barley and rye, the toxic counterparts of gliadin are 
named hordein and secalin, respectively. These proteins confer properties such as 
viscosity and cohesivity, making gluten an attractive ingredient in the baking of 
voluminous bread. A common feature of these proteins is that they are rich in 
glutamine and proline and are poorly digested in the upper gastrointestinal tract by 
gastric, pancreatic and intestinal brush-border membrane proteases66, 67.  
 
 
 
Figure 1. Taxonomy of the grains involved in CD. 
As seen in Figure 1, oats are closely related to wheat, barley and rye, belonging to the 
same subfamily. Avenin, the prolamine in oats, has not been shown to induce CD other 
than anecdotally68, 69. Oats are generally considered a safe ingredient of a gluten-free 
diet70, although precautions must be made to avoid contamination with gluten. Other 
grains, such as rice and maize, contain low levels of proline and glutamine and do not 
confer CD.  
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2.3.3 Immunological mechanisms 
In individuals with CD, incompletely digested gluten peptides cross the intestinal 
epithelial barrier. The mechanisms allowing a breach of this barricade that is otherwise 
impermeable to macromolecules remain undisclosed. Increased intestinal permeability 
due to infections or other stress factors have been suggested to play a role in CD 
pathogenesis71. Additionally, there are some evidence suggesting a paracellular 
pathway due to dysfunctional tight junctions72. Furthermore, studies have shown 
increased transcellular transportation of intact gliadin molecules in individuals with 
active CD73, 74. 
 
Upon reaching the lamina propria, gluten peptides are deamidated by the enzyme tissue 
transglutaminase-2 (tTG) (Figure 2). TTG is expressed by many cell types and 
associates with the extracellular matrix. TTG targets glutamine residuals in extra- and 
intracellular proteins. It may also covalently link with gluten peptides. When gluten 
peptides are deamidated, the residual peptide is negatively charged and binds even 
stronger to HLA-DQ2 (or DQ8) molecules on antigen presenting cells (APCs; 
macrophages, B-cells and/or dendritic cells). These cells then activate CD4+ T-cells 
that release inflammatory mediators upon activation. The inflammatory mediators, 
mainly IFNγ and TNFα, activate matrix metalloproteinases that cause epithelial cell 
damage and tissue remodelling75. Gluten specific T-cells activate B-cells leading to 
clonal expansion and antibodies against gluten peptides and tTG. Almost all individuals 
with CD will have developed autoantibodies against tTG76.   
 
The adaptive immunity response to gluten peptides in CD has been fairly well 
described. Interestingly, findings suggest that certain peptide residues, different from 
the ones that trigger the adaptive immune system, elicit an innate immune response in 
CD. After binding to epithelial cells or APCs, intra-epithelial lymphocytes (IELs) and 
natural killer cells are activated by means of IL-15. This leads to epithelial cell killing 
and increased intestinal permeability. Thus, the adaptive and innate immune responses 
work in concert to achieve intestinal inflammation, crypt hyperplasia and villous 
atrophy (VA); the characteristic hallmarks of CD. 
  8 
 
 
Figure 2. Immunological pathways in CD. 
Reprinted from Gastroenterology, 137, Schuppan D, Junker Y, Barisani D. Celiac Disease: From 
Pathogenesis to Novel Therapies, 1912-1933, 2009 with permission from Elsevier.  
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2.3.4 Environmental factors 
Genetics are important in CD, but do not qualify as sufficient causes. Pathologic 
immunological mechanisms have been elucidated, but are not fully understood. An 
environmental offender, gluten, has been identified. Yet current research offers no tool 
of anticipating or preventing the development of CD in patients. It is increasingly clear 
that CD is a multifactorial disease, in which the interplay of genetic and environmental 
factors other than gluten contributes to disease occurrence. In Finland, screening 
studies showed a 1.5% prevalence of CD autoantibodies among children age 7-16 
years77, but 2% among screened adults17. This indicates increased CD development 
over time in susceptible individuals, and further denotes the importance of 
environmental risk factors (or protective factors) in CD pathogenesis.  
 
2.3.4.1 Infant feeding practice 
 
The first two years of life represent a challenging period for children’s nutrition and 
health. The velocity of growth is rapid, and the metabolic rate is high. In addition, the 
infant’s immune system and gastrointestinal function is immature, limiting possible 
food sources and rendering the infant sensitive for food-borne infections78.  
 
The current WHO guidelines on breastfeeding recommend exclusive breastfeeding 
during the child’s first six months of life79. Exclusive breastfeeding is defined as the 
consumption of no other food or liquids except breast milk and small amounts of 
medicines or vitamin-mineral supplements. At 6 months of age, complementary 
feeding should be introduced in order to fulfill the child’s energy and nutrition 
requirements.  It is recommended that breastfeeding be continued until two years of 
age, or beyond80. Guidelines offered by the Swedish Board of Health and Welfare 
(Socialstyrelsen) and the National Food Agency (Livsmedelsverket) regarding 
breastfeeding duration have been modified to comply with WHO standards (Figure 3).  
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Figure 3. Infant feeding recommendations in Sweden over time 
 
In 1985-1987 the incidence of CD in children 0-2 years of age increased dramatically, 
from 50-60 cases per 100,000 person-years to 200-240 cases per 100,000 person-years 
(see Figure 4)58. This incidence remained elevated until 1995, when the incidence rate 
dropped to the same level as before the so-called “Swedish epidemic”. The start of the 
epidemic coincided with increased consumption of gluten containing cereals in 1981-
1983 and recommendations from the Swedish pediatric society to postpone gluten 
introduction until 6 months of age (see Figure 3). The end of the epidemic, in 1995, 
concurred with an increased number of children being breastfed at time of gluten 
introduction (from 54% to 76%), reduced consumption of gluten flour in the first year 
of life, and changed recommendations regarding breastfeeding suggesting that parents 
introduce gluten from 4 months of age whilst continuing breastfeeding58. In all, the 
“Swedish epidemic” supports the hypothesis that infant feeding practice affects the risk 
of CD in children. 
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Figure 4. Incidence of CD in Swedish children aged 0-2 years over time. 
Reprinted from Best Practice & Research Clinical Gastroenterology, 19(3), Ivarsson A. The Swedish 
epidemic of coeliac disease explored using an epidemiological approach—some lessons to be learnt, 
425-441, 2005 with permission from Elsevier.  
 
Michaelsen et al compared the intake of wheat at 9 and 12 months of age in Danish 
compared with Swedish infants and found that Swedish infants had a substantially 
larger wheat intake81. Interestingly, Danish CD incidence rates have been reported 
lower than those of other European countries82. One study found higher incidence of 
CD in Swedish compared with Danish children with comparable breastfeeding patterns 
but earlier gluten introduction in the Danish group83. Interestingly, Swedish children 
presented with CD symptoms at a significantly lower age (mean 1.5 vs 5.5 yrs, p 
<0.01). It has been suggested that early (<3 months of age39 or < 2 months of age84) or 
late (>7 months of age)39 introduction of breastfeeding increase the risk of CD. 
However, Ivarsson et al found that a greater number of healthy individuals had a late 
(after 7-12 months) gluten introduction when compared to individuals with CD85.  
 
Several studies have investigated the effect of breastfeeding on the risk of CD. 
Although most studies suggest a greater risk for CD in infants with shorter 
breastfeeding duration84-88, research findings are inconsistent 89-91. The majority of 
these studies were retrospective. Furthermore, it is unclear whether a shorter duration of 
breastfeeding reduces the risk of CD or merely delays disease onset. It has also been 
debated if the postulated effect of breastfeeding on CD may be best understood by later 
gluten introduction upon weaning in these babies. A recent meta-analysis including 6 
studies84-89 showed that breastfeeding at time of gluten introduction may be protective 
of future CD (pooled odds ratio (OR) 0.48, 95% CI 0.40-0.59) (see Figure 5).  In 
conclusion, the body of previous research suggests that infant feeding practice is a 
factor that affects CD pathogenesis.   
 
 
 
  12 
 
Figure 5. Odds ratios (95% CI) of effect of breast-feeding at the time of gluten 
introduction on development of CD. 
Reproduced from [Effect of breast feeding on risk of coeliac disease: a systematic review and meta-analysis 
of observational studies, Akobeng AK, Ramanan AV, Buchan I, Heller RF, 91, 39-43, 2009] with 
permission from the BMJ Publishing Group Ltd. 
 
 
2.3.4.2 Microflora and perinatal factors 
 
It has been hypothesized that an altered bacterial intestinal flora might impact the risk 
of CD. Indeed, individuals with CD seem to have different metabolic characteristics of 
their microflora compared to healthy controls92. Interestingly, these differences in fecal 
microflora composition were evident in treated as well as in untreated celiacs92, and in 
screening detected cases93. Previous studies have suggested increased risk of CD in 
individuals delivered by elective caesarean delivery91 A recent case-control study found 
increased risk of CD in elective caesarean deliveries (adjusted OR, 1.15; 95% CI 1.04 –
1.26) but not in emergency caesarean deliveries94. In elective caesarean deliveries, all 
children have avoided contact with the maternal vaginal bacterial flora. The positive 
association with elective caesarean delivery thus supports the hypothesis that an altered 
gut microflora confers an increased risk of CD.  
 
Maternal smoking during pregnancy is reported to confer a small risk increase of CD in 
offspring (OR, 1.10; 95% CI 1.01-1.19)95, however, another study reported a higher 
estimate (Relative risk, 2.12; 95% CI 1.19–3.79)90. Being small for gestational age has 
been shown to increase the risk of future CD (OR, 1.45; 95% CI 1.20-1.75)95. Neonatal 
infections, prospectively reported in a register study, conferred an increased risk of 
future CD (OR, 1.52, 95% CI 1.19–1.95)95. 
 
2.3.4.3 Infectious disease 
 
Seasonal variance in incidence is a common characteristic of infectious diseases. It’s 
therefore interesting that individuals born in the summer suffer increased risk of CD 
(RR, 1.4; 95% CI 1.2- 1.7)96. Could infectious disease be an environmental factor of 
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interest in CD pathogenesis? Indeed, Stene et al found increased risk of CD 
autoimmunity in children with higher rotavirus infection frequency (rate ratio for trend 
per increase in number of infections, 1.94; 95% CI 1.04–3.61, p = 0.037)97. 
Additionally, Decker et al found a nearly threefold risk of postnatal GI disorders, 
including GI infections, in children with CD. No associations with other infections 
were found91. Lastly, Kagnoff et al reported increased levels of anti-adenovirus 
antibodies in individuals with CD98. Since a particular adenovirus protein share amino 
acid sequence homology with gliadin, the authors hypothesized that perhaps certain 
antigens can confer an increased CD risk by immunological cross reactivity. Another 
potential mechanism whereby infectious disease could affect CD pathogenesis is by 
increased intestinal permeability. 
 
In conclusion, there are a number of environmental factors suggested to play a role in 
CD pathogenesis, including infant feeding practice and infectious disease. Many 
questions, however, remain unresolved. Is breastfeeding really protective of CD or are 
current studies merely reporting a symptom delay or recall bias? Or is the true offender 
a high gluten load during infancy? Furthermore, what is the role of infectious disease in 
CD pathogenesis? Under what circumstances, if any, can an infection trigger CD, and 
which are the relevant pathogens?   
 
 
2.4 CLINICAL PRESENTATION 
CD was initially described as a syndrome of steatorrhea, diarrhea, and malabsorption in 
children99. A classic mode with GI symptoms as the dominating symptoms at 
presentation has become less common over time in children and adults100, 101. Overall, 
there has been a shift towards milder symptoms, likely due to increased use of CD 
serology. Before 1993, 73% of adults with CD presented with diarrhea. This symptom 
was less common after 1993 (43%) when serologic testing was introduced as a 
diagnostic tool102. At the Celiac Disease Center at Columbia University, New York, the 
most common modes of presentation in adults were diarrhea (40%), anemia (15%), 
screening (10%), bone disease (6%) and incidental findings at upper endoscopy (6%). 
In children, the most common findings were growth issues (26%), screening (23%), 
abdominal pain (22%) and diarrhea (9%)11. Weight loss is an uncommon symptom of 
CD, and it is of clinical importance to note that CD may occur also in overweight 
individuals103.  
 
The spectrum of clinical presentations in modern CD is wide, from asymptomatic CD 
detected upon screening in at-risk populations, to disease with extra-intestinal 
manifestations (atypical disease), and, lastly, “classic” CD. Although CD is defined as a 
lesion of the small-intestinal mucosa, the following symptoms and disorders may 
suggest CD and warrant investigation: ataxia, anemia52, neuropathy, depression, 
osteoporosis, chronic thrombocytopenic purpura, Addison’s disease, and tuberculosis11. 
 
In conclusion, there has been a shift in the presentation of CD over time. This shift may 
be explained by changed disease characteristics; however, a more likely explanation is 
a coinciding development of diagnostic tools104.   
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2.5 DIAGNOSING CELIAC DISEASE 
2.5.1 Diagnostic criteria 
Current diagnostic criteria for CD are based on guidelines issued by the European 
Society for Pediatric Gastroenterology and Nutrition (ESPGHAN)105 and have been 
extrapolated to adults106-108. For a CD diagnosis, characteristic small intestinal mucosal 
abnormalities are required, as well as clear-cut clinical remission on a strict gluten-free 
diet. A positive CD serology that reverts to normal after dietary treatment strengthens 
the suspicion of CD, but is by itself not enough to establish the diagnosis. Small 
intestinal biopsy remains the gold standard in diagnosing CD. In asymptomatic patients 
and in cases with a weak clinical response upon initiation of dietary treatment a control 
biopsy is required to verify histological remission on a gluten-free diet. A biopsy after 
gluten provocation may be useful in individuals with unclear diagnosis, and should be 
considered in children less than 2 years of age 109.   
 
A recent consensus paper suggested definitions of CD and related disorders (see Table 
2)110.  
 
Table 2. The Oslo definitions110 of CD and related disorders.  
 
 
 
 
CD  A chronic small intestinal immune‐mediated enteropathy precipitated by exposure to dietary gluten in genetically predisposed individuals.   Asymptomatic CD  CD not accompanied by symptoms even in response to direct questioning at initial diagnosis.  Classical CD  CD presenting with signs and symptoms of malabsorption. Diarrhoea, steatorrhoea, weight loss or growth failure is required.  Non classical CD  CD presenting without signs and symptoms of malabsorption.  Subclinical CD  CD that is below the threshold of clinical detection.  Potential CD  Individuals with a normal small intestinal mucosa who are at increased risk of developing CD as indicated by positive CD serology.  CD autoimmunity  Increased tTG or EMA on at least two occasions when status of the biopsy is not known. If the biopsy is positive, then this is CD, if the biopsy is negative than this is potential CD.  
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2.5.2 The use of serological tests 
Serological testing has since the 1990’s developed into an important tool in determining 
which individuals should undergo small intestinal biopsy. This practice has led to an 
increased understanding of the CD spectrum. Furthermore, it has contributed to an 
understanding that CD is a more common disorder than previously thought.  
 
Antibodies against gliadin (AGA), endomysium antibodies (EMA) and tissue 
transglutaminase antibodies (tTG) are commonly considered. The use of AGA (IgG 
and IgA) is limited, due to a comparatively low sensitivity and specificity (see Table 
3)76. In children < 18 months of age, AGA in combination with tTG is preferred since 
many children lack EMA and tTG111. In adults and children > 18 months, EMA or tTG 
are recommended whereas AGA is not. A recently developed assay for antibodies 
against deamidated gluten peptides seems promising and may be used to increase 
diagnostic accuracy in children112.  
 
 
Table 3. Performance of serologic screening tools in CD76.  
   Sensitivity (95% CI)  Specificity (95% CI)  Prevalence IgA AGA adult  0.75‐0.90 H  0.80‐0.90 H  36% IgA AGA children  0.80‐0.95 H  0.80‐0.95 H  36% IgA EMA ME adult  0.974 (0.957‐0.985)  0.996 (0.988‐0.999)  40% IgA EMA ME children  0.961 (0.945‐0.973)  0.974 (0.963‐0.982)  40% IgA tTG HR adult  0.981 (0.901‐0.997)  0.981 (0.958‐0.991)  40% IgA tTG HR children  0.957 (0.903‐0.981)  0.990 (0.946‐0.998)  40% 
HR, human recombinant; ME, monkey esophagus. 
H= significant heterogeneity according to Pearson’s chi square test.   
 
The endomysium is a connective tissue protein found in collagenous matrix 
surrounding smooth muscle cells. The EMA test uses either monkey esophagus or 
human umbilical cord as substrate. The occurrence of antibodies is measured with an 
immunoflourescent staining technique that requires manual evaluation107. In 1997, 
Dietrich et al identified tTG as the antigen in EMA113, leading to the development of 
ELISA methods for tTG. Nowadays, most laboratories use human recombinant tTG as 
substrate. Even though the EMA outperforms the tTG in terms of specificity, tTG has 
important advantages being less expensive and labour intensive, quantitative instead of 
operator dependent, quicker and not using primate tissue. In conclusion, most studies 
report sensitivities and specificities for tTG and EMA > 95%, and both tests are 
considered useful in CD diagnostics114.  
 
IgA deficiency is a state where an individual has decreased levels of IgA but normal 
levels of serum IgG and IgM. In selective IgA deficiency, no IgA at all can be detected. 
Selective IgA deficiency is ten times more common in individuals with CD115, 
therefore total IgA needs to be assessed when performing serological tests in suspected 
CD. If selective IgA deficiency cannot be ruled out, IgG EMA and IgG tTG tests can 
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be used56. Since these have lower specificity and sensitivity116 than IgA based tests, 
biopsy may be considered independently of IgG serology results.  
 
Henceforward, the term “CD serology” is defined as a term that includes endomysium-, 
transglutaminase-, or deamidated gliadin antibodies, and in small children also gliadin 
antibodies for the assessment of CD110.  
 
CD serology has a high specificity for CD76 and a high negative predictive value 
(NPV). A high NPV makes CD serology particularly useful in ruling out the disease, 
stating that the likelihood of not having the disease is high if the test is negative. In 
contrast, the positive predictive value (PPV) of CD serology is dependent on the 
prevalence of the disorder. Consider a sensitivity of 99%. One case in 100 cases tested 
will have a false-positive test result. Given a CD prevalence of 1%56, the test will yield 
2 positive results of which 1 is negative, and the PPV will be 50%, i.e. the probability 
of having CD given a positive CD serology is low. In studies by Hopper et al117 and 
Hadithi et al118, the NPV of tTG screening was >99% with reported PPV at 28.6% and 
73% respectively in populations with a 3.9% and 3.46% CD prevalence. The low PPV 
is an important feature of CD serology that supports the continued use of small 
intestinal biopsy before prescribing a life-long dietary treatment. Another important 
aspect is the fact that seronegative CD does occur117, thus biopsy is recommended 
irrespective of negative CD serology in the light of high CD suspicion105. The increased 
availability of over-the-counter rapid antibody tests119 may lead to individuals initiating 
a gluten-free diet without prior biopsy.  
 
 
2.5.3 Genetic testing 
Since virtually all individuals with CD are HLA-DQ2 or DQ8 positive61, a negative 
HLA test is forceful in ruling out the disease, i.e. the NPV is very high. However, since 
these HLA types will also be found in about 1/3 of the general population62, a positive 
result will merely confirm the possibility of CD. A positive test result is not in itself 
suggestive of CD, since only 3% of individuals carrying these alleles will develop CD. 
A HLA test may be particularly useful in ruling out CD in IgA deficient individuals or 
individuals with high heredity for CD, and in individuals on a GFD who have not 
undergone biopsy,  
 
2.5.4 Small intestinal biopsy 
Small intestinal biopsy is the gold standard of diagnosing CD56. The indication for 
small intestinal endoscopy and biopsy is often a positive CD serology. In a Swedish 
study, 100% of pediatricans and 96% of gastroenterologists reported that they perform 
small intestinal biopsy in at least 9/10 patients prior to establishing a CD diagnosis120.  
 
The mucosal changes seen in CD, originally classified by Marsh121, is a spectrum 
ranging from near-normal mucosa to intestinal inflammation and VA. Marsh stage I is 
characterized by increased counts of intraepithelial lymphocytes (IELs) (>30 IELs per 
100 epithelial cells), and stage two of raised IELs in conjunction with crypt hyperplasia 
(Figure 6). Marsh I and II are considered early changes in individuals predisposed to 
CD, however these abnormalities may be caused by GI disorders other than CD, such 
as giardiasis, helicobacter pylori gastritis and viral gastroenteritis (see Table 5)122. 
Marsh stage III is divided in 3 groups; Marsh type IIIa (partial VA), Marsh type IIIb 
(subtotal VA) and Marsh type IIIc (total VA) (Figure 6). An overview of small 
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intestinal histopathological classifications is offered in Table 4. Swedish intestinal 
biopsies are classified according to the SnoMed system, that is based on the same 
criteria as the Marsh classification for duodenal and jejunal biopsies.    
 
Table 4. Overview of small intestinal histopathology classifications in CD. 
Classification Villous atrophy (VA) 
Marsh 
classification 
Stage IIIa Stage IIIb Stage IIIc 
Marsh description Flat, destructive 
SnoMed codes M58, D6218, M58005 M58, D6218, M58006 M58, D6218, M58007 
KVAST/Alexand
er classification 
III  Partial VA IV Subtotal VA IV  Total VA 
 
 
 
 
 
 
 
Figure 6. Marsh stages 0 (normal, upper left), I (upper right), II (lower left) and III 
(lower right). Acknowledgement, dr Marjorie Walker, Histopathology, Faculty of Medicine, Imperial 
College London  
 
The celiac lesion may be patchy, therefore it is recommended that 4-6 biopsies are 
acquired from the proximal small intestine56, including one biopsy specimen from the 
duodenal bulb123, to increase the likelihood that VA is detected should it be present. In 
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CD, macroscopic aberrations might be present such as mucosal scalloping, an absence 
of folds, and a mosaic pattern of the mucosa between the folds. However, since only 
total and subtotal VA may be visible macroscopically, this visualization should not 
replace biopsy. Biopsy specimens should be of sufficient size, carefully oriented and 
mounted with the villous side up, allowing for cross sectioning rather than tangential 
sectioning which might be misleading.  
 
All that is flat is not CD, but most often VA is CD. In a Swedish data-set, 95% 
(108/114) of patients with VA had CD, indicating that the specificity of CD in VA is 
high120. Internationally, other causes of VA may be more common (Table 5)122. 
 
 
Table 5. Differential diagnoses to consider in CD investigation122.  
 
Increased intraepithelial lymphocytes – Allergies to proteins other than gluten (eg, chicken, cow’s milk, eggs, fish, rice and soy; entities cause both raised intraepithelial counts and villous architectural changes) – Autoimmune conditions, various (eg, systemic lupus erythematosus) – Bacterial overgrowth – Blind loop syndrome – Dermatitis herpetiformis – Giardiasis – Graft‐versus‐host disease – Helicobacter pylori – Inflammatory bowel disease – Irritable bowel syndrome – Microscopic colitis – Non‐steroidal anti‐inflammatory drugs – Tropical sprue (entities cause both raised intraepithelial counts and villous architectural changes) – Viral enteritis 
Crypt hyperplasia or villous flattening – Allergies to proteins other than gluten (eg, chicken, cow’s milk, eggs, fish and soy; entities cause both raised intraepithelial counts and villous architectural changes) – Autoimmune enteropathy – Collagenous sprue – Common variable immunodeficiency – Drug‐induced – Hypogammaglobulinaemic sprue – Ischaemia – Kwashiorkor – Radiation therapy – T cell lymphoma, associated enteropathy ‐ Zollinger–Ellison syndrome 
 
 
  19 
2.5.5 To screen or not to screen?  
The WHO has established criteria for mass screening (Table 6)124. CD fulfils several of 
these criteria; about 2/3 of individuals with CD are asymptomatic125, it is a common 
disorder with a prevalence of about 1% worldwide 56, and there is an available 
treatment (GFD). Yet screening in CD is debatable, for several reasons. The low PPV 
of celiac serology117, 118 would result in a large number of false-positive  tests, which 
may cause harm in terms of anxiety and unnecessary small-intestinal biopsies.  It would 
also lead to a large increase in health-care workload and be costly. One can question the 
availability of a treatment; adherence to a GFD is expected to be low in screening 
detected cases. Furthermore, current research has not reached a consensus regarding the 
benefits of a GFD in individuals with asymptomatic disease, and we cannot rule out a 
complete lack of benefits provided by a GFD in asymptomatic CD. Canavan et al found 
no increased mortality in individuals with undiagnosed CD126, however, another study 
found a four-fold increased risk of death in individuals with undiagnosed CD18. 
Furthermore, Corrao et al found increased mortality in individuals with CD and signs 
of malabsorption (standardized mortality rate (SMR), 2.5; 95% CI 1.8-3.4) but not in 
those diagnosed because of minor symptoms127. 
 
Do interventions reduce the risk of complications in asymptomatic CD? How should 
we treat individuals with potential CD (positive CD serology but normal mucosa)? Will 
these individuals benefit from a GFD? These questions will likely require answers 
before national screening can be recommended. However, there is some support for 
screening or active case finding in high risk groups128. Screening in high risk groups 
and in individuals with symptoms is a feasible and cost-efficient strategy that has the 
additional advantage of raising awareness regarding CD129.  
 
Table 6. The WHO criteria124 for mass screening.  1. The condition should be an important health problem. 2. There should be a treatment for the condition. 3. Facilities for diagnosis and treatment should be available. 4. There should be a latent stage of the disease. 5. There should be a test or examination for the condition. 6. The test should be acceptable to the population. 7. The natural history of the disease should be adequately understood. 8. There should be an agreed policy on whom to treat. 9. The total cost of finding a case should be economically balanced in relation to medical expenditure as a whole.  10. Case‐finding should be a continuous process, not just a "once and for all" project. 
 
2.6 TREATMENT 
2.6.1 The gluten-free diet 
When the CD diagnosis is established, a life-long gluten-free diet (GFD) is prescribed. 
This is currently the only available treatment for CD. The GFD is devoid of wheat, 
barley and rye. Symptom reduction is usually reported after days or weeks after 
initiation of treatment56, however mucosal abnormalities may persist. Lee et al noted 
  20 
that only 21% of individuals on a GFD had normal mucosa after an average of 8.5 
years of treatment130.  
 
The acceptance of wheat starch and oats in the diet of individuals with CD has been 
debated but is currently accepted in many European countries including Sweden. 
Available studies suggest that oats may be safely introduced in the diet of adults131, 132 
and children70, 133 with CD. In many regions, however, the inclusion of oats is not 
consistently recommended due to high levels of cross contamination with gluten-
containing grains during growing, transportation and milling56. Wheat-starch derived 
gluten-free products contain trace amounts of gluten. A randomized study comparing 
individuals including these products in their diet with individuals on a natural GFD 
found no differences in morphological and clinical response134.  
 
Even though an ideal diet for an individual on CD is strictly gluten-free, this is not 
realistic given gluten contamination of gluten-free products135. It has been calculated 
that the average GFD contains 20-100 parts per million (ppm) gluten/day. The “safe 
threshold” of gluten intake has been debated. Catassi et al suggested that daily gluten 
intake should rest below 50 mg/day, based on a prospective double-blind placebo 
controlled trial with histologic examination136.  Given a daily gluten-free flour 
consumption of 80 g, Collin et al suggested an accepted daily intake of 100 ppm (30 
mg)135. The WHO Codex Alimentarius updated it’s guidelines in 2008, stating that 
naturally gluten-free foods can contain up to 20 mg gluten/kg (20 ppm) and 100 mg 
gluten/kg in wheat starch-derived gluten-free products137. These recommendations 
obviously set out to prevent mucosal damage in CD patients and they reflect current 
knowledge regarding gluten tolerance in CD. However, another important aspect is the 
availability and cost of gluten-free products. Should the diet be too awkward and 
expensive, adherence rates would likely decrease. According to the Swedish Consumer 
Agency, CD infers increased yearly food costs of about 2760 SEK (€290) for children, 
3890 SEK (€410) for women and 4715 SEK (€500) for men138. A few counties in 
Sweden currently provide subsidies to individuals with CD.     
 
At diagnosis, vitamin status should be assessed by measuring the serum folate, vitamin 
B12, and vitamin D (25-hydroxy) in patients with CD. Deficiencies should be 
substituted. The GFD and gluten-free products are often deficient of fiber, iron, 
calcium, vitamin D, magnesium, folate, niacin, B12 and riboflavin139. Few gluten-free 
products are enriched, and vitamin B deficiency may develop even after ten years of 
adherence to a GFD140. Therefore, all patients are advised to take a gluten-free 
multivitamin11.  
 
Although the GFD accomplishes symptom relief in most patients and mucosal 
improvement, albeit imperfect, in some, the treatment is challenging. There are 
currently several ongoing research projects investigating the possibility of nondietary 
treatments in CD, for which there exists an unmet need. Interesting substances in 
pipeline include oral proteases for gluten detoxification (phase I+II), 
immunomodulatory substances including monoclonal antibodies, and a peptide 
vaccination (phase I) 141. In the longer perspective, increased understanding of 
environmental factors in the development of CD could enable primary prevention 
strategies.  
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2.6.2 Benefits of a gluten-free diet 
In individuals with symptomatic CD, the most obvious benefit of the GFD is a swift 
clinical improvement characterized by subjective and objective symptom relief. Studies 
show that treatment with GFD improves bone mineralization in children142 and 
adults143, reverses anemia and iron deficiency144, and restores body composition in 
children145.  In individuals with gastro-intestinal symptoms (classic CD), quality of life 
is improved after initiating a GFD146. No consensus has been reached regarding the 
effect of GFD on quality of life in individuals with asymptomatic CD146-148.  
 
Upon initiation of a GFD, clinical, serological and histological improvement should 
follow. Mucosal recovery is not instant. Lee et al reported that only 21% of individuals 
on a GFD had normal mucosa after an average of 8.5 years of treatment130. Similarly, 
Hopper et al noted that one third (16/48) of patients on a GFD for one year had 
remaining VA at follow-up biopsy149. It was noted that 44% (7/16) of individuals with 
VA had seroconverted after one year of GFD, suggesting that tTG antibody titres 
correlate poorly with mucosal lesion severity149.  
 
It has been suggested that adherence to a GFD reduces mortality127, risk of autoimmune 
disorders150 and lymphoma in CD151. Ventura et al reported increased risk of 
autoimmune disorders in individuals with CD diagnosed after 10 years of age (23.6%), 
compared with individuals diagnosed before 2 years of age (5.1%, p < 0.001)150, 
suggesting that duration of exposure to gluten may affect the risk of complications in 
CD. Adherence to a GFD has been associated with decreased mortality rate127, 
however, a prospective cohort study reported decreasing mortality ratios with 
increasing age at CD diagnosis152. It is important to note that a direct causality of gluten 
exposure duration on the risk of comorbidity and mortality and CD has not been 
formally tested. Studies merely imply an association without disentangling duration of 
gluten exposure from age at CD diagnosis. Furthermore, few studies include enough 
follow-up time to assess the risk of outcomes common in adulthood, such as cancer, in 
children diagnosed with CD.  
 
In conclusion, individuals with clinically detected CD seem to benefit from the GFD in 
terms of symptom relief and reversal of clinical abnormalities, as well as reduced risk 
of future complications. Research available to date is non-conclusive when it comes to 
benefits of the GFD in individuals with screening detected CD.  
 
2.6.3 Achieving and monitoring adherence 
The GFD is a complicated treatment that requires an active and well-informed patient. 
To optimize adherence, newly diagnosed patients should receive information and 
medical nutritional education from skilled dieticians. There are patient support groups 
in many regions, contributing valuable forums. The patient with CD should be 
evaluated at regular intervals by a multi-professional health care team including a 
physician and a dietician. Follow-up visits should include assessment of adherence, 
physical examination, assessment of symptoms as well as growth, particularly in 
children. At these visits, the GFD should be promoted. The responsible physician 
should be aware of common complications in CD such as osteoporosis, vitamin 
deficiencies and other autoimmune disorders, and test for these when symptoms appear.  
 
There is no optimal method to monitor dietary adherence. Although EMA positivity did 
not predict mucosal recovery, it correlated with reported poor dietary adherence in 80% 
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of cases153. EMA or tTG positivity after 1 year of treatment is indicative of poor dietary 
adherence154. Although CD serology might be helpful, assessment of dietary adherence 
by trained interviewers is recommended, since this method is non-invasive, 
inexpensive, and correlates with mucosal revocery155. 
 
In the care of individuals with CD, it may be useful to consider varying adherence 
rates. The level of adherence achieved has been reported lower in individuals with 
screening detected CD compared with individuals diagnosed due to symptoms156, 
although a Finnish study found no difference between the groups157. A Swedish study 
reported higher adherence rates in individuals diagnosed at an age of < 4 years of age 
compared with individuals diagnosed later in life (80% vs. 36%)158.  
 
2.6.4 Non-responsive CD 
It is common that individuals with CD respond poorly to the GFD. In a study by Leffler 
et al, non-responsive CD was defined as a failure to respond to a GFD of at least 6 
months, or the re-occurrence of symptoms or laboratory abnormalities typical of CD 
whilst on a GFD155. 10-19% of individuals with CD fulfilled these criteria. The most 
common reasons for the unresponsiveness were dietary transgressions (36%), IBS 
(22%) and refractory CD (RCD) (10%).  
 
When unresponsive CD is discovered, further investigations should include; 1) re-
evaluation of the initial CD diagnosis including exclusion of other causes of VA; 2) 
assessment of dietary compliance and; 3) CD serology that might indicate dietary 
transgressions56. If poor adherence is detected, contact with a dietician, referral to a 
support group and regular follow up is warranted. Non-responsive CD in individuals 
with strict adherence warrants further investigations to exclude the occurrence of 
intestinal malignancies or refractory CD.   
 
 
2.7 ASSOCIATED DISORDERS 
Individuals with CD suffer increased risk of a number of associated disorders and 
complications, such as malignancies, death, liver disease, anemia, thyroid disease and 
depression. Some associations, such as osteoporosis and anemia, are caused by 
nutritional deficiencies, some by shared genetics. The mechanisms underlying other 
associations remain poorly understood. Some complications of relevance are discussed 
below.  
 
2.7.1 Mortality in CD 
With few exceptions159, research has shown an increased risk of death in CD. A recent 
Swedish prospective population-based cohort study showed increased risk of death in 
CD (HR, 1.39; 95% CI 1.33-1.45)152. This estimate is lower than those reported by 
previous studies160, 161, likely due to the increased use of antibody screening rendering 
cases diagnosed at a lower disease activity. Furthermore, most previous studies were 
based on inpatients or few clinical units, presenting a selection bias favoring the 
inclusion of individuals with complicated disease. Significantly increased mortality 
ratios due to cardiovascular disease, respiratory disease, and malignancies were 
reported152.  
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2.7.2 Dermatitis herpetiformis 
Dermatitis herpetiformis is a cutaneous manifestation of CD. It is a blistering skin 
condition usually located on knees, elbows, buttocks and scalp. Diagnosis is made after 
skin biopsy. Most individuals with dermatitis herpetiformis have signs of mucosal 
inflammation and/or VA. The rash responds to a GFD, however in a delayed fasion. 
Treatment with dapsone is usually administered to relieve the rash during GFD 
initiation162.  
 
2.7.3 Refractory CD 
Refractory CD (RCD) is defined by the presence of persistent or recurrent 
malabsorptive symptoms (e.g. diarrhea, abdominal pain or weight loss), and VA despite 
strict adherence to a GFD for at least 12 months, in the absence of other causes of non-
responsive CD and malignancy and after confirmation of the initial CD diagnosis163. 
RCD is a diagnosis of exclusion. In RCD, patients may never have responded to 
treatment or relapsed despite adherence and initial response. CD serology is most often 
negative, however a positive test does not rule out RCD. In establishing RCD, a careful 
assessment of GFD adherence must be performed. In RCD type I, IELs have a normal 
phenotype whereas RCD type II is characterized by an aberrant IEL population56. The 
existence of a clonal aberrant T-cell population is prognostic; in individuals with RCD 
II mortality is high (five-year mortality rate 40-58%) mainly due to an increased risk of 
enteropathy-associated T-cell lymphoma (EATL). The prognosis of RCD type I is 
much better164, although the rate of complications and mortality seems to be 
significantly higher than in responsive CD165.  
 
Treatment of RCD includes nutritional support and repletion of vitamins and minerals, 
as well as support to achieve a strict GFD. Corticosteroids have induced improvement 
in most cases, immunosuppressive drugs may be beneficiary, and autologous 
hematopoetic stem-scell transplantation have been successful56. 
 
2.7.4 Malignancy 
CD is associated with an increased risk of overall malignancy, malignant lymphoma, 
and gastrointestinal malignancy (small-intestinal, oropharyngeal, esophageal, large 
intestinal, hepatobiliary, and pancreatic carcinomas 166), but reduced risk of breast 
cancer166 and lung cancer167. A recent study of biopsy-verified CD showed increased 
risk of GI malignancies only during the first year after CD diagnosis168 suggesting that 
the symptoms of GI malignancy lead to CD diagnosis.  
 
 
2.8 COMPLICATIONS STUDIED IN THIS THESIS 
2.8.1 Study I: Venous thromboembolism  
Venous thromboembolism (VTE) is a major source of morbidity and mortality world-
wide169. VTE has been linked to chronic inflammation (IBD)170, and autoimmune 
disease (diabetes mellitus)171. Several case reports suggest a positive association 
between CD and VTE172-176. An Austrian study found no association between CD and 
VTE, although it was originally designed to study IBD and included only a small 
number of patients170.  
 
  24 
High serum levels of homocysteine is considered a risk factor for VTE177-179, although 
one study found no positive effect of homocysteine lowering by vitamin 
supplementation on the risk of VTE180.  Homocystein is a sulfur amino acid that is 
metabolized in pathways requiring vitamin B12, folate, and vitamin B6181. Individuals 
with CD suffer a three-fold increased risk of hyperhomocysteinemia at time of 
diagnosis182, likely due to vitamin deficiencies. In the study by Saibeni et al, folate and 
homocysteine levels correlated with mucosal lesion severity, and most patients 
normalized vitamin levels and homocysteine levels after initiation of a GFD182. It is 
important to note that mucosal aberrations may persist for years in treated CD130, and 
that there is evidence of vitamin B6 and folate deficiency as well as 
hyperhomocysteinemia even after 8-12 years of GFD140. These notions support the 
hypothesis that hyperhomocysteinemia may cause an increased risk of VTE in CD. 
Other suggested mechanisms that may contribute to an increased risk of VTE in CD 
include high levels of thrombin-activatable fibrinolysis inhibitor (TAFI)183 and a 
positive association between CD and anti-phospholipid syndrome184.  
 
2.8.2 Study II: End-stage renal disease 
End-stage renal disease (ESRD), defined by the need of renal replacement therapy 
(dialysis or transplantation) is a severe and costly disorder. The Swedish prevalence of 
ESRD was 867 per million people (PMP) in 2008185 and has increased to 904 PMP by 
the end of 2010186, with a stable incidence of 125 per million person-years185. In 
Sweden, diabetic nephropathy is the most common reason for incident ESRD, whereas 
primary glomerulonephritis is the most common underlying disorder in prevalent 
ESRD185. The prevalence of ESRD is increasing worldwide187. Underlying reasons are 
poorly understood, however, increased prevalence of diabetes mellitus is an important 
contributor188.   
 
Previous research has led to a suspicion that impaired oral tolerance may be associated 
with renal disease. Indeed, patients with primary glomerulonephritis often display an 
activated mucosal immune system189, increased gut permeability190, 191, and an 
increased number of mucosal intra-epithelial T-lymphocytes190. Furthermore, CD 
autoantibodies have been observed in individuals with renal disease192, 193 and some 
renal disease will improve on a low-antigenic diet lacking in gluten194.   
 
Previous research has suggested an association between CD and renal disease161, 195, 196. 
Collin et al showed an increased prevalence of CD among individuals with IgA 
nephropathy195. Peters et al showed an increased mortality rate of nephritis in 
individuals with CD (Standardized mortality rate, 5.4)161, and this finding was 
supported by a study from our group reporting an increased risk of dialysis (HR, 3.48; 
95% CI 2.26 – 5.37) and renal transplantation (HR, 3.15; 95% CI 1.29 – 7.71) in CD196. 
These studies161, 196 were limited to in-patient diagnoses of CD.  
 
2.8.3 Study III: IgA nephropathy 
IgA nephropathy (IgAN) is an immune-complex mediated glomerulonephritis. It was 
first described by Berger and Hinglais in 1968197. IgAN is the most common type of 
primary glomerulonephritis in the world198, occurring in 15-40 PMP and year in 
Europe, with progression to end-stage renal disease in 15-50% of cases199. It is the most 
common type of glomerulonephritis underlying ESRD in Sweden186. IgAN is 
diagnosed through renal biopsy where the biopsy specimen is examined by light 
microscope, immunoflourescense (IF) or immunohistochemistry (IH) studies, and 
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electron microscopy. Although there is a wide range of histological abnormalities that 
may be present upon examination, the most common alteration identified by light 
microscope is an expansion of mesangial regions. IH/IF examinations should 
demonstrate a predominant deposition of IgA antibodies in conjunction with symptoms 
suggestive of IgAN to establish the diagnosis199.  
 
In IgAN, the clinical presentation may vary from asymptomatic disease to macroscopic 
haematuria and impaired renal function. The “classic” presentation of IgAN includes 
macroscopic haematuria and impaired renal function coinciding with infections of the 
upper respiratory tract. Although the pathogenesis of IgAN is unknown, a role for 
impaired oral tolerance has been implied200. An increased number of IELs190, increased 
prevalence of CD autoantibodies192, 193, 201, 202, and increased gut permeability191 have 
been reported in IgAN. Furthermore, improvement of parameters such as proteinuria 
and microscopic haematuria upon initiation of a GFD has been reported in IgAN194, 203, 
204. 
 
In earlier studies assessing the association between CD and renal disease, no specific 
information on the presence of IgAN was available161, 196, 205. In 2002, Collin et al found 
a high prevalence of CD (3.6%) among 223 consecutive patients with IgAN195. 
Furthermore, prevous case reports206, 207 and one small study202 have suggested an 
association between CD and IgAN, however results are inconclusive208. 
 
a.            b.   
 
 
 
 
Pictures on this page by courtesy of associate professor Birgitta Sundelin, department of 
Pathology, Karolinska University Hospital, Stockholm, Sweden.  
 
Figure 7A. (Left) Hematoxylin staining, light microscopy, renal biopsy. B. (Right) 
Immunoflourescense microscopy, renal biopsy. * = Mesangial IgA depositions 
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3 AIMS 
The overall aim of this thesis was to achieve an increased understanding of the 
pathogenesis and the burden of complications in CD. CD is a common disorder 
worldwide, and the most common chronic disorder among children. Sweden is well 
suited for epidemiological studies by the use of national health data registers and 
national quality registers providing high quality data.  
 
To ameliorate the understanding of disease burden in CD, the following specific aims 
were considered  
- To explore if the risk of hospital admission due to venous thromboembolism is 
increased in CD; 
- To assess the risk of CD among individuals with venous thromboembolism;  
- To investigate the risk of renal disease (end-stage renal disease and IgA 
nephropathy) in individuals with biopsy-verified CD; 
- To assess the risk of CD in individuals with prior renal disease.  
 
Regarding the role of infections in CD pathogenesis, the specific aim was to 
- Investigate if infection at time of gluten introduction is a risk factor for future 
CD.  
 
  27 
4 SUBJECTS AND METHODS 
 
4.1 DATA SOURCES 
4.1.1 National health data registers 
4.1.1.1 The Swedish patient register 
 
The National Board of Health and Welfare has collected information on individual 
hospital discharges in Sweden since 1964. Psychiatric diagnoses were added in 1973, 
and complete national coverage in the Swedish hospital discharge register was reached 
by 1987. Validation studies have shown high specificity, with positive predictive values 
of about 85-95% for most diagnoses209. From 1997, surgical day care procedures are 
reported, and since 2001, all hospital-based outpatient visits have been reported to the 
Swedish outpatient register209. For every patient visit or discharge, these patient 
registers provide information regarding diagnosis and surgical procedures according to 
the International classification of diseases (ICD).  
 
The Swedish patient register was used to identify exposure (study I) and outcome 
measures in study I (Swedish hospital discharge register) and study II. It was also used 
to identify covariates in studies I-III, and prior renal disease in studies II and III.  
 
4.1.1.2 The total population register 
 
The Swedish total population register (TPR) is kept by Statistics Sweden. It contains 
data on basic demographics such as the personal identity number, sex, age, civil status, 
area of residence, country of birth and date of emigration. Information is collected and 
continuously updated by local tax offices. The register was computerized in 1968210. 
We used the TPR to select matched reference individuals and to collect data for 
censoring (emigration date or death) in studies I-III.  
 
4.1.2 The Swedish renal register 
The Swedish renal register (SRR) is a national quality register originally established in 
1991. Individuals with renal replacement therapy (dialysis or transplantation) are 
reported to the register, and all Swedish renal treatment units participate. In a validation 
study, coverage was reported at >95%211.  
 
We used the SRR to validate the outcome (ESRD) in study II, and to access data on 
underlying disease causing renal failure.  
 
4.1.3 The educational register 
Information regarding educational level (seven pre-defined levels) was obtained 
through Statistics Sweden. In children, the education level of the parents is recorded. 
Data on education level are used as a proxy for socioeconomic position. Missing data 
could concern people with degrees from abroad or with private degrees or with internal 
company-educations, or people with old degrees. 
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4.1.4 The Swedish prescribed drug register 
The Swedish prescribed drug register contains all prescribed drugs dispensed to 
Swedish residents at pharmacies in Sweden since July 1, 2005, and has an almost 99% 
coverage212. Data from the register were used to identify individuals for whom 
antihypertensive agents were dispensed in study II.  
 
4.1.5 Small intestinal biopsy data 
Small-intestinal biopsy is the golden standard of diagnosing CD, performed in at least 
9/10 cases by 100% of Swedish pediatricians and by 96% of Swedish 
gastroenterologists prior to diagnosing CD 120. Data from small intestinal biopsies 
performed between July 1969 and February 2008 were collected between October 27, 
2006, and February 12, 2008. This was achieved through computerized searches of all 
(n=28) pathology departments in Sweden. Searches were carried out by local 
technicians and rendered data on the arrival date of biopsy material, personal identity 
number, morphology according to SnoMed classification codes (villous atrophy, M58) 
and topography (duodenum/jejunum). CD was defined as VA (equal to Marsh stage III) 
of the duodenum or jejunum. 29,096 individuals of biopsy-verified CD were identified. 
The mean age at first recorded small intestinal biopsy with VA was 30 years. The 
majority of individuals were diagnosed in adulthood and after 1990.  
 
4.1.6 Renal biopsy data 
Renal biopsy examination by light microscopy and immunofluorescence or 
immunohistochemistry has been the gold standard for IgAN diagnosis in Sweden since 
the 1970s. Computerized records are available since the early 1990s in all of Sweden. 
Renal biopsies are assessed at four pathology departments in Sweden (Stockholm, 
Gothenburg, Linkoping, and Malmö/Lund). Individuals with IgAN were identified by 
computerized searches in all four departments, using relevant SnoMed coding (IgAN, 
D67300). In one department (Malmö/Lund), coding had not been registered. Therefore, 
data from all renal biopsies from this department were obtained and manually scanned 
(AW and BS). Individuals from this region were considered to suffer from IgAN only 
when the pathologist’s report described findings consistent with IgAN and the 
pathologist clearly stated IgAN as the primary diagnosis. We collected data on 4,069 
unique individuals with a biopsy record of IgA nephropathy in Swedish computerized 
biopsy registers.  
  
4.1.7 The ABIS study 
Infants born in Southeast Sweden between October 1, 1997, and October 1, 1999, were 
invited to participate in the ABIS (All Babies in Southeast Sweden; the counties of 
Öland, Småland, Blekinge and Östergötland) cohort project. This project was launched 
to examine the role of environmental factors in the development of immune-mediated 
disease. Of the 21,700 infants born during the study period, parents of 17,055 gave 
informed consent for participation. 16,286 mothers completed an initial birth 
questionnaire at the maternity ward or at home. Parents were asked to keep a diary 
during the child’s first year of life, providing data on factors such as diet (date of 
cessation of breastfeeding and gluten introduction) and infectious diseases (date of 
infection). These diaries were filled out prospectively at home by the parents of 9,849 
children. We restricted our study to 9,408 children for whom complete data on 
breastfeeding duration and gluten introduction were provided by the diaries.  
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The majority of children with CD in the ABIS cohort were identified through a study 
on symptoms and signs in CD101.  In this study, all eight pediatric departments 
undertaking small intestinal biopsies in children from the ABIS area registered children 
with CD. CD was defined as VA upon small-intestinal biopsy and (1) resolution of all 
symptoms after introduction of a GFD and/or (2) no or only minor histopathologic 
abnormalities of CD in the biopsy taken during treatment with a GFD. The ABIS 
population was not actively screened for CD. In 2007–2008, these pediatric 
departments were again contacted and asked to report on children in the ABIS study 
with biopsy-verified CD (VA). CD-consistent symptoms and antibody markers were 
required for the diagnosis of CD. Data collection in the ABIS study is described in 
Figure 8.  
 
  
Figure 8. Data collection in the ABIS study 
 
4.1.8 The Swedish personal identity number  
The Swedish personal identity number (PIN) is an important tool that enables linkage 
of data from Swedish health data registers. Since 1947, the National Tax Board has 
assigned a ten-digit PIN at birth or immigration to all individuals that have resided in 
Sweden. The first six numbers are the date of birth (year-month-day), followed by three 
digits identifying the individual and a last digit (control digit). The PIN is used by all 
health care providers in Sweden, allowing virtually 100% coverage of the Swedish 
health care system213.  
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4.2 STUDY DESIGN 
4.2.1 Study I 
This study is a population-based prospective cohort study. Individuals with CD  (n= 
14,207) were identified in the Swedish hospital discharge register (Figure 9). Five 
reference individuals, matched for age, sex, calendar year and county at the time of CD 
diagnosis, were selected for each individual with CD using the TPR (n= 69,048). 
 
Figure 9. Data collection in study I. 
Follow-up started 1 year after CD diagnosis, to minimize the risk of detection bias due 
to hospital admittance in CD, and ended at death, emigration, date at first discharge 
diagnosis of VTE or  31st of December, 2003, whichever came first.  The risk of future 
VTE in individuals with CD was calculated using Cox regression. Analyses were 
performed stratum wise, which means that each individual with CD was only compared 
with his/her reference individuals. In separate analyses, we stratified by age (≤15 years 
vs. >15), and sex. Diabetes mellitus is a potential confounder, being positively 
associated with VTE171, and with CD36. We therefore adjusted for diabetes mellitus in a 
separate analysis. Additionally, we adjusted for socio-economic index since this might 
be associated with the predisposition of seeking medical care.  
 
Lastly, we performed a retrospective case-control study based on the aforementioned 
cohort. Conditional logistic regression was used to estimate the association between 
CD and prior VTE. To avoid detection bias, those with one year or less between VTE 
and study entry (CD diagnosis) were excluded.  
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To determine whether a potential risk increase for VTE is specific for CD or associated 
with surveillance bias, post hoc analyses were performed restricting reference 
individuals to individuals with a record of being inpatients within 1 year prior to or 
after the index case with CD. This analysis was not internally stratified due to the fact 
that many reference individuals were excluded; instead we adjusted for age, sex and 
calendar period.   
 
4.2.2 Studies II and III 
These studies are population-based prospective cohort studies. Individuals with CD 
were identified through Swedish biopsy registers (see above). Study entry was defined 
as date of CD diagnosis (biopsy with VA) or corresponding date in reference 
individuals. Outcome measures (ESRD or IgAN) were identified using the Swedish 
patient registers and the SRR (study II) and a database of biopsy-verified IgAN 
collected from Swedish pathology departments (study III). Up to five reference 
individuals per index person matched for age, sex, calendar period and county, were 
identified using the TPR. We excluded individuals for whom patient registers or the 
SRR indicated ESRD prior to study entry (study II) and individuals with any record of 
renal disease in patient registers or biopsy with IgAN prior to study entry (study III).  
Data linkage in studies II and III is described in Figure 10.  
 
 
Figure 10. Data linkage in studies II and III. 
 
Follow up ended at date of ESRD/IgAN diagnosis, emigration, death or the 31st of December 
2008, whichever came first. Analyses were performed stratum-wise (each individual was 
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performed only with his/her controls). 
 
Diabetes mellitus type 1 is associated with CD36  and renal disease and is thus a 
potential confounder to be considered in studies II and III. Because early versions of 
Swedish ICD coding (ICD7-9) do not distinguish between type 1 and type 2 diabetes, 
we defined diabetes mellitus as a diagnosis of diabetes reported to the Swedish patient 
register before the age of 30 years. Liver disease is positively associated with CD214 but 
may also cause renal IgA deposits (secondary IgAN)215.  We therefore adjusted for liver 
disease in study III, obtaining information on this covariate from the Swedish patient 
register. Analyses performed in studies II and III are described in Table 7.   
 
Table 7. Analyses performed in studies II and III.   Study II  CD n= 29,050 Reference individuals n= 144,363 
Study III  CD n= 27,160 Reference individuals  n= 133,949 
Stratified analyses  Age Sex Calendar period Follow‐up 
Age Sex Calendar period Follow‐up 
Adjusted analyses  Diabetes mellitus type 1 Education level Country of birth  Any renal disease prior to  study entry  
Diabetes mellitus type 1 Education level Country of birth  Liver disease  
Additional analyses  Risk of subsequent CD in individuals with ESRD  Outcome restricted to ESRD in patient register AND in the SRR  Adjustment for use of any hypertensive drugs  
Risk of subsequent CD in individuals with IgAN 
 
In both studies, we performed additional case-control studies assessing the risk of 
future CD in individuals with ESRD or IgAN. This was done using conditional logistic 
regression, with study entry at time of ESRD/IgAN and the end of study at first 
diagnosis of CD.  These analyses were performed to evaluate whether the association 
between CD and the outcome is restricted to patients with CD preceding the outcome, 
thus providing further information on the temporal sequence of the association (see 
Figure 11). If the primary analysis shows a positive association between CD and future 
IgAN/ESRD (black arrow) this suggests that the characteristics of CD increase the risk 
of IgAN/ESRD. If, concomitantly, the risk of future CD in IgAN/ESRD is elevated, 
this suggests shared genetics or environmental factors in the two disorders (red arrows). 
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If, however, the risk of future CD in IgAN/ESRD is elevated, but not the reverse, this 
suggests that the characteristics of IgAN increases the risk of CD (green arrow).  
 
 
Figure 11. Potential flow of associations in studies II and III.  
In a separate analysis we examined the risk of ESRD in prior CD adjusting for 
hypertension. Since the sensitivity for hypertension is low in the Swedish hospital 
discharge register216,we used anti-hypertensive medication as a proxy for hypertension. 
Data on such medication were obtained through the Swedish prescribed drug register. 
We used the ATC codes (Anatomical, Therapeutical and Chemical classification 
system) C02, C03 C07 and C08 to identify individuals with hypertension (anti-
hypertensive medication). In a post hoc subanalysis we then adjusted for 
antihypertensive medication in patients with follow-up until at least July 1, 2005, when 
the Swedish prescribed drug register started.  
 
4.2.3 Study IV 
This is a prospective cohort study. Using data from the ABIS cohort, we calculated the 
risk of future CD in children with any infectious disease or gastroenteritis at time of 
gluten introduction, adjusting for age at gluten introduction and age at end of 
breastfeeding. The reference group consisted of children from the ABIS cohort for whom 
dietary data were completed and no diagnosis of CD was observed. After discussions 
regarding the incubation periods of different infectious diseases and their potential effects 
on the immune system (A. Ternhag, MD, PhD, personal verbal communication, 2008) 
time of gluten introduction was defined as 3 weeks prior to gluten introduction or in the 
week immediately following gluten introduction (see Figure 10). We defined 
gastroenteritis as a parent-reported episode of repeated vomiting, diarrhea, or stomach flu. 
Follow-up started at one year of age, to avoid potential recall bias. Follow-up ended on 
June 30, 2006 or date of CD diagnosis, or death.  
 
Data were analyzed in several steps. Initially, we compared infectious load during the 
first year of life in children with and without CD using the Mann Whitney U-test. 
Univariate analyses included stratification for age initially exposed to gluten, age at end 
of breastfeeding, and age at any infection or gastroenteritis. Bivariate analyses included 
analyses adjusted for age initially exposed to gluten and age at any infection, and age at 
end of breastfeeding. In our final, multivariate analysis, we tested the association between 
future CD and parent-reported infection (any infection or gastroenteritis) at time of gluten 
introduction (Figure 12) whilst adjusting for age at end of breastfeeding, age at gluten 
introduction, and age at any infection (or gastroenteritis).   
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Figure 12. Infection at time of gluten introduction. 
 
4.3 STATISTICAL METHODS OF RELEVANCE 
4.3.1 Cox proportional hazards model (studies I-IV) 
David R. Cox first proposed the Cox proportional hazards model in 1972 217. It has 
since become the most commonly used statistical model applied in medical time-to-
event studies218. A classic example of a time-to-event study is the study of survival time 
after a sombre diagnosis. The Cox proportional hazards model is constituted of a 
baseline hazard function (h0 (t)) and an exponential function (see Equation 1). The 
baseline hazard function is unspecified (non-parametric), whereas the exponential 
function is completely specified, apart from the unknown parameters (parametric); thus 
the full Cox model is considered semi-parametric. The Cox model assumes 
proportional hazards, i.e. that the difference in risk between groups is constant over 
time.  
   h(t | x1, x2,…, xk) = ho(t)exp(β1x1+ β2x2+…+βkxk)  
 
Equation 1. The Cox proportional hazards model  
The output of interest in Cox modeling is the hazard ratio (HR).  The hazard is the risk 
of the outcome, for example death, at a given time interval t+ Δt given survival to time 
t. The hazard ratio is the relative hazard comparing two groups, assuming that they 
meet the criteria of proportional hazards. If this criterion is not met, estimated HRs will 
be misleading.  
 
We used Cox regression to estimate risk of CD in study IV, and to estimate the risk of 
subsequent complications in individuals with CD in studies I-III.  For these studies, we 
used an internally stratified approach (each individual with CD was compared with 
his/her matched reference individual prior to pooling of the estimates). Log-minus-log 
curves showed that the proportional hazards assumption was valid (example curve, see 
Figure 13).   
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Figure 13. Log-minus-log curve, study III. 
 
4.3.2 Logistic regression (studies I-III) 
Logistic regression is used to model the association between one or several independent 
variables (covariates) and a binary outcome variable. With a binary (or dichotomous) 
outcome variable, what is modeled is the logit transformation of the odds (π) of the 
outcome given x (Equation 2).  
  π (y | x) = {eβo + β1x/(1+ e βo + β1x}  ln(π(x)/(1‐ π(x))= β0+β1x 
 
Equation 2. Logistic regression model and logit transformation.  
 
This transformation is important and desirable, since it shares properties with the 
familiar linear regression model. It is continuous and linear, with the potential for a 
range of - ∞- y- +∞, given x. The basis for the model is the method of maximum 
likelihood, whereby advanced software produces estimates for the coefficients that 
maximize the probability of obtaining the observed set of data219.  
  
Logistic regression makes a few assumptions. Firstly, each observation must be 
independent. Multicolinearity is not tolerated (independent variables must be 
independent from each other). Logistic regression does not require the independent 
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variable to be linearly correlated with the dependent variable. It does, however, require 
linearity between the independent variable and the logit.  
 
An intuitive interpretation of risk is to consider the probability (p) of disease in a 
population. Another way to calculate risk is to divide the number of patients who 
contracted the disease over the number of patients who did not, producing the odds of 
the event (p/(1-p)). The output of interest in logistic regression is the odds ratio (OR), 
which can be calculated from the estimated coefficient β1. The odds ratio is defined as 
the cases’ odds of having been exposed to a certain risk factor (x), divided by the 
reference individuals’ odds of having been exposed to the same risk factor. Note that 
the probability (p) of y given x (Equation 2) can be reduced to p/(1-p). 
 
4.3.2.1 Conditional logistic regression  
 
In conditional logistic regression, the association between being a case or not being a 
case and a set of prognostic factors is assessed stratum-wise.  This is often used in 
matched case-control studies. The difference from regular logistic regression is that 
each individual is compared only with his/her matched cases, thus minimizing the 
effect of the matching variables. An option could be to use unconditional logistic 
regression and instead include the matching variables in the analysis. This, however, 
will lead to an overestimation of the OR.  
 
We used conditional logistic regression in nested case-control studies in studies I-III, 
when we assessed the risk of subsequent CD following VTE/ESRD/IgAN. In these 
studies, time-to-event was not considered.  
 
 
4.4 ETHICAL CONSIDERATIONS 
Study I: This project (04-030/1) was approved by the Research Ethics Committee of the 
Karolinska Institute, Stockholm, Sweden on the 18th of March 2004.  
Study II: This project was approved by the Research Ethics Committee of the 
Karolinska Institute, Stockholm, Sweden on the 31st of April, 2006 (dnr 2006/633-
31/4).  
Study III: This project was approved by the Research Ethics Committee of the 
Karolinska Institute, Stockholm, Sweden on the 31st of April, 2006 (dnr 2006/633-
31/4). Additions to this project is also described and approved by the same committee 
(dnr 2010/407-31/1).  
Study IV: This study is part of the ABIS project, which was originally approved by the 
Research Ethics Committees of the Faculty of Health Sciences, University of 
Linköping (Li 287-96) and the Medical Faculty, University of Lund (Lu 83-97).  
 
Studies I-III are register-based cohort studies, based on information independently 
collected from patients as part of a standardized process. Given the temporal volume of 
data collected in national registers, a substantial number of individuals included in these 
studies are likely dead. The ethics committee requested us not to contact any 
participants of these studies, since this would likely cause more harm than patient 
benefits. Abstaining from informed consent is customary in Swedish large-scale 
register based studies. All data were made anonymous prior to analysis to protect 
patient privacy.  
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5 RESULTS 
5.1 COMPARING THE COHORTS (STUDIES I-III) 
There are some differences between the CD cohort characteristics in study I vs. studies 
II-III that are of value to consider when interpreting the results. Briefly, individuals 
with CD in study I were median 2 years of age at CD diagnosis, compared with a 
median age of about 30 years of age in the biopsy cohort. Furthermore, the majority of 
individuals with CD in study I were diagnosed before 1994 (74.9%), whereas 85.9% 
were diagnosed after 1990 in studies II-III. In studies I-III, CD was more common in 
women (ratio of circa 6:4), and type 1 diabetes mellitus occurred more frequently in 
individuals with CD compared with reference individuals. This implies that studies II-
III investigates a more modern CD cohort, with a greater number of individuals 
diagnosed with CD in adulthood. These characteristics likely reflect the increased use 
of CD serology over time, and increased awareness that CD may present in adulthood.  
 
 
5.2 CD AND VENOUS THROMBOEMBOLISM (STUDY I) 
Of 15,439 individuals with CD, 406 (2.6%) suffered subsequent VTE, compared with 
1105/76,910 (1.4%) of reference individuals. We found a modestly increased risk of 
future VTE in individuals with CD (HR, 1.86; 95% CI 1.54-2.24). This risk increase 
was seen in men and in women, and remained significant when the first year of follow-
up was included. Stratified analyses showed no increased risk of VTE in individuals 
diagnosed with CD before the age of 16, however heterogeneity testing suggested no 
significant difference in risk according to age at CD diagnosis (p= 0.072). The estimate 
remained significant in analyses adjusted for diabetes mellitus and socieoeconomic 
index. No difference in risk of VTE was seen with respect to sex (p= 0.739) or age (p= 
0.072). The risk increase was lower when we restricted reference individuals to 
inpatients (HR, 1.27; 95% CI 1.06-1.52).  
 
Conditional logistic regression revealed increased risk of subsequent CD in individuals 
with prior VTE (HR, 1.67; 95% CI 1.34-2.06).  
 
5.3 CD AND END-STAGE RENAL DISEASE (STUDY II) 
Among 29,050 individuals with CD, 90 (0.3%) developed ESRD, compared with 
152/144,363 (0.1%) in reference individuals. This corresponds to an incidence rate of 
ESRD in individuals with prior CD of 30/100,000 person-years, and 10/100,000 
person-years in reference individuals.  
 
We found a nearly three-fold increased risk of future ESRD in individuals with prior 
CD (HR, 2.87; 95% CI 2.22-3.71). The most common underlying renal disease in 
individuals with CD and in reference individuals was diabetes nephropathy. The 
estimate remained significant in analyses adjusted for the presence of diabetes mellitus 
type 1, education level, or country of birth (Nordic vs. non-nordic). Excluding 
individuals with records of any renal disease prior to CD diagnosis had little effect on 
the estimate (HR, 2.47; 95% CI 1.80-3.40). When we restricted ESRD to individuals 
with a record of ESRD in a patient register and in the SRR, the risk estimate was 
slightly elevated (HR, 3.06; 95% CI 2.34-4.01). Upon stratification for modality of 
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treatment, we found an increased risk of dialysis (HR, 3.06; 95% CI 2.34-4.01) but not 
renal transplantation (HR, 1.55; 95% CI 0.67-3.62) in individuals with CD. 
 
Separately, we examined the association between prior ESRD and CD using 
conditional logistic regression (case-control design). Individuals with prior ESRD 
suffered an increased risk of later CD (Odds ratio (OR), 2.45; 95% CI 1.74-3.44). 
 
 
5.4 CD AND IGA NEPHROPATHY (STUDY III) 
Of 27,160 individuals with CD and no prior renal disease, 7 developed IgAN (0.03%), 
corresponding to an incidence of 25 PMP and year. Among reference individuals, the 
incidence rate was 8 PMP and year (11 cases of IgAN, 0.008%).  We found an 
increased risk of biopsy-verified IgAN in individuals with biopsy-verified CD (HR, 
3.03; 95% CI 1.22-7.56). Although interaction tests revealed no difference in risk of 
IgAN according to sex (p= 0.32), only one woman developed IgAN and stratified 
analyses showed increased risk for future IgAN only in men. Due to lack of power, 
analyses stratified by age at CD diagnosis, year of CD diagnosis and length of follow-
up yielded increased HRs but wide confidence intervals including 1, or could not be 
calculated due to a lack of positive events. No individuals suffered from diabetes 
mellitus type 1. The risk estimate remained increased after adjusting for country of 
birth (HR, 2.96; 95% CI 1.19-7.37) and education (HR, 2.73; 95% CI 1.03-7.26). The 
risk estimate remained significantly increased after adjusting for any liver disease (HR, 
3.19; 95% CI 1.27- 8.06).  
 
We used conditional logistic regression (case-control design) to calculate 
odds ratios (ORs) to assess the association between prior IgAN and CD.  
We found no increased risk of future CD in individuals with IgAN (OR, 1.70; 95% CI 
0.70-4.12 (data adjusted for age, sex, and calendar year). 
 
5.5 INFECTION AT TIME OF GLUTEN INTRODUCTION AND RISK OF 
FUTURE CD (STUDY IV) 
At end of follow-up (Dec 1st, 2006), study children were aged 8 years and there were 50 
cases of CD, corresponding to a prevalence of diagnosed CD of 1:188 children 
(0.53%). Six of the children with CD received their diagnosis during their first year of 
life and were therefore excluded from the main analyses. 92.4% of children had at least 
one parent-reported infection during their first year of life (average number of 
infections, n= 4.6). In total, we had data on 42,826 episodes of infectious disease, 
reported with date of onset. 34.1% of children had at least one episode of parent-
reported gastroenteritis during their first year of life. The follow-up time in the 9,408 
children (CD n=44), starting at age 1 year, was 68,206 person-years. Except where 
explicitly stated, all analyses were restricted to these 9,408 children.  
 
5.5.1 Breastfeeding duration, introduction of gluten and risk of CD 
No individual with CD had received gluten in the first three months of life, as 
compared to 1.1% of reference individuals. Almost half of participating children were 
breastfed for more than 10 months. Gluten was most often introduced during months 5 
and 6. Age at gluten introduction or end of breastfeeding was not associated with future 
CD.  
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5.5.2 Any infection, gastroenteritis and risk of CD 
Infection at time of gluten introduction was associated with an increased risk of future 
CD (HR, 1.9; 95% CI 1.0-3.4; P = 0.038), while gastroenteritis at time of gluten 
introduction was not (HR, 1.3; 95% CI 0.2-9.4) (unadjusted analyses). In a final model, 
adjusted for age at gluten introduction, age at end of breastfeeding and age at infection 
(or gastroenteritis), we found no statistically significant association between infection at 
time of gluten introduction and future CD (adjusted HR, 1.8; 95% CI 0.9-3.6; p = 
0.111). Additionally, gastroenteritis at time of gluten introduction was not significantly 
associated with increased risk of future CD (adjusted HR, 2.6; 95% CI 0.2-30.8; p = 
0.439).  
  40 
6 DISCUSSION 
 
6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Study design 
6.1.1.1 Cohort studies (I-IV) 
 
Randomized clinical trials are considered the standard of excellence with the highest 
degree of evidence for evaluations in health care220. Experimental studies may, 
however, not be always be feasible nor appropriate. Observational studies are thus 
warranted in medical research. Epidemiological studies are cohort studies, case-control 
studies, or variations of the two. Choosing between the two is generally a trade-off 
between validity and efficiency.  
 
In cohort studies (from the Latin cohors, plural cohortes, used to describe a military 
unit) groups of individuals sharing similar pre-defined exposure types (e.g. CD and 
reference individuals) are followed over time and the incidence rate of the outcome of 
interest is compared between the different cohorts yielding estimates of relative risk221. 
Cohort studies are generally considered to have a higher validity than case-control 
studies, suitable for studies where the exposure of interest is rare, and practical since 
they provide estimates of absolute risk. They are, however, often expensive and time 
consuming. Although these disadvantages may be true for some cohort studies, 
historical cohorts based on national registers have different characteristics. Swedish 
national registers contain data that are prospectively collected, minimizing the risk of 
recall bias. Data are registered in different registers without knowledge of planned 
studies, a practice that minimizes the risk of biased registrations. The time consumption 
is reduced since the cohorts are already initiated and outcomes registered. Additionally, 
the costs of these studies are independent of the study size. A disadvantage with 
historical cohort studies is that data collection rarely is designed with regards to the 
studies being undertaken. Thus, a lack of detail may limit availability of exposure data 
and information regarding potential confounders.  
 
6.1.1.2 Case-control studies (I-III) 
 
Case-control studies are a cost-efficient approach to study the relationship between 
exposure and outcome in epidemiological studies. This design is also suitable when the 
outcome of interest is rare, and a cohort study would be inefficient. Cases are 
individuals that develop the outcome, and the controls do not. Comparing the frequency 
of exposure in the two groups in a retrospective manner enables assessment of whether 
the exposure is a risk factor for the outcome. The validity of a case-control study relies 
heavily on the comparability of cases and controls. Since only a sample of the study 
base is collected, absolute risks and incidences rates cannot be calculated in a case-
control study. The output of interest is commonly the odds ratio (OR), defined as the 
odds that a case is exposed divided by the odds that a control is exposed. The 
interpretation of the OR is analogous to the RR obtained in cohort studies, but will 
overestimate RRs>1 and underestimate RRs <1 when the outcome becomes more 
frequent222.  
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6.1.2 Internal validity 
In the context of epidemiological studies, internal validity is the extent to which the 
study de facto measures what it set out to do, i.e. how the inferences drawn pertain to 
the subjects that are under study. In contrast, external validity is concerned with the 
generalizability of study results, i.e. how inferences drawn relate to individuals outside 
the study population218. Two types of errors threaten the internal validity; random error 
and systematic error (bias).  
 
6.1.2.1 Recall bias 
 
Recall bias is the effect of prior knowledge regarding outcome status affecting 
retrospective reports of exposure status, and is a common issue in case-control studies. 
Recall bias makes cases and controls less comparable, since cases may be more prone 
to recall exposure than controls (increasing sensitivity among cases) or more likely to 
construct false memory of exposure (reducing specificity among cases), or the disease 
itself may cloud the memory.  
 
In contrast to earlier studies on infant feeding practice and CD85-87, exposure data in 
study IV were collected prospectively in an attempt to minimize recall bias. We cannot 
exclude that for some children, parents delayed diary completion and filled it in 
retrospectively at the end of the child’s first year of life. At this time, although not yet 
having received a diagnosis of CD, initial disease symptoms may have increased the 
awareness and carefulness of diary completion among parents, introducing potential 
recall bias however to a presumably low extent.   
 
6.1.2.2 Selection bias 
 
Selection bias refers to biases that result from the procedure of selecting study 
participants and from factors that influence participation. Common examples are the 
healthy worker effect223, volunteer bias, inappropriate selection of controls in case-
control studies, and differential loss to follow-up. In brief, due to selection bias the 
groups under study are not comparable and the association between exposure and 
disease is different for those included in the study compared with the underlying study 
base.  
 
In study I, exposure status was determined by data from the Swedish hospital discharge 
register. This imposes a risk of selection bias, since individuals requiring hospital 
admission may have a more severe disease than the average individual with CD. This 
selection bias would be more pronounced if all individuals were diagnosed today, but 
in the study most individuals were identified in the 1980’s and 1990’s when 
hospitalization was more common. Additionally, the median age at study entry was two 
years. Since young children often need anesthesia for biopsy acquirement, 
hospitalization would be more common in this group. We therefore believe that this 
cohort is largely representative of the celiac population during the study period.  
 
To avoid selection bias due to hospitalization, we used national biopsy registers to 
assess exposure status in studies II-III. A differential degree of outcome registration 
(VTE, ESRD, IgAN) due to exposure status (CD) cannot be ruled out but seems 
unrealistic. Due to the use of national registers to sample reference individuals, all 
Swedish residents have the same probability of being included, provided they had no 
record of an earlier small intestinal biopsy.   
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Although the ABIS cohort is population based, the analyses were restricted to children 
whose parents chose to participate in the study and for whom the diary was sufficiently 
completed. We cannot rule out that participating parents were more prone to comply 
with dietary guidelines and that their infant’s risks of CD subsequently would differ 
from the general population. Since >95% of diaries contained complete data on 
breastfeeding and gluten introduction, we consider the risk of selection bias due to 
diary completion very low.     
 
6.1.2.3 Detection bias 
 
Detection bias, or surveillance bias, is common in epidemiological studies and arises 
when exposure leads to increased or decreased likelihood of observing the outcome. In 
study I, we cannot exclude that individuals with CD admitted to a hospital suffer 
increased risk of the outcome due to increased awareness of symptoms and check-up 
visits that might lead to the diagnosis of a VTE. To minimize the risk of detection bias, 
we excluded individuals with follow-up less than 1 year in our main analysis. 
Additionally, we performed separate analyses restricting our reference individuals to 
inpatients.  
 
We cannot rule out that part of the risk increase observed in study II is caused by 
surveillance bias. Since a significantly increased risk of ESRD remained even after 5 
years after CD diagnosis, such bias is unlikely to explain all of the risk increase 
observed. Surveillance bias might inflate the risk estimate, since increased risk of future 
dialysis (which implies frequent blood sampling and physician visits) but not renal 
transplantation was observed.  
 
6.1.2.4 Misclassification  
 
Information bias, or misclassification, is defined as an error in measurement of the 
exposure or outcome. Differential misclassification occurs when the error depends on 
the other variables (i.e. misclassification of exposure depends on outcome) whereas 
non-differential misclassification arises when there is a measurement error of 
exposure/outcome that is independent of the other variables. Differential 
misclassification may lead to under- or overestimation of the associations in 
observational studies. Non-differential misclassification biases any risk estimate 
towards the null value, obscuring any real differences218. Recall bias or detection bias 
are two examples of differential misclassification.  
6.1.2.4.1 Misclassification – discharge diagnoses of CD and VTE  (study I) 
 
Although no study has assessed the validity of the discharge diagnoses of CD or VTE 
in the Swedish hospital discharge register, validation studies have confirmed a high 
overall quality, with positive predictive values of about 85-95% for most diagnoses209. 
In a small patient chart review, the positive predictive value of CD in the Swedish 
hospital discharge register was 77%, but this study was limited to patients diagnosed 
with CD mostly in old age151. A high specificity for CD is not surprising since prior 
small-intestinal biopsy preceding diagnosis has been required since 1969.  
 
Considering the sensitivity of CD in the hospital discharge register, it is likely not as 
high as the specificity, however we believe that we have included a considerable 
portion of Swedish individuals with diagnosed CD. The reference population likely 
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includes some false-negatives given that undiagnosed CD is common224, however not 
to an extent that is likely to affect the estimate given a prevalence of CD of 1% on the 
population level. Sweden has roughly 9 million inhabitants. An earlier Swedish study 
of diagnosed CD showed a prevalence of about 1/1000224. We included 14,207 
individuals with CD in the current study.  
 
6.1.2.4.2 Misclassification- diagnosis of CD in Swedish biopsy registers (study II and III) 
 
A recent validation study confirms that small intestinal biopsy indeed remains the gold 
standard in diagnosing CD. 96% of Swedish gastroenterologists and 100% of Swedish 
paediatricians report that they perform a small intestinal biopsy in at least 9/10 
individuals prior to diagnosing CD120. It is therefore likely that we have identified the 
vast majority of cases of diagnosed CD in Sweden. There will likely exist false-
negatives among the reference individuals, however to a low extent given the 
prevalence of the disease.   
 
All that is flat is not VA, however. The same validation study examined a subset of 
biopsy reports and found that conditions other than CD was rare in VA120. Among 114 
patients with VA, 95% had a clinical diagnosis of CD. The specificity of CD in VA is 
thus high.  
6.1.2.4.3 Misclassification- diagnosis of ESRD  (study II) 
 
Validation studies have confirmed a high overall quality of diagnoses in the Swedish 
hospital discharge register, with positive predictive values of about 85-95% for most 
diagnoses, which renders little risk of misclassification of ESRD209. In individuals with 
CD, increased contact with health care and work-up including blood samples may lead 
to increased recognition of renal disease. We therefore conducted an analysis where we 
restricted the outcome to ESRD reported in the patient register and in the Swedish 
Renal Register (SRR), to minimize the risk of misclassification of disease (i.e. increase 
the sensitivity of ESRD in our study). The risk estimate remained significant after this 
restriction. 
 
In our study, we report an incidence of 100 PMP among reference individuals. This 
number is similar to what has been reported on a national level (125 PMP186), which 
further supports appropriate classification of outcome.  
6.1.2.4.4 Misclassification- diagnosis of IgAN in Swedish biopsy registers (study III) 
 
No previous studies have assessed the quality of the IgAN diagnosis in Swedish biopsy 
registers. We cannot exclude the possibility of misclassification of disease. Although 
renal biopsy is required for a diagnosis of IgAN199, the procedure is invasive and entails 
a risk of bleeding and renal damage. Biopsy may be avoided in cases of mild renal 
disease225, resulting in a risk of false-negatives among reference individuals. Since 
IgAN is uncommon, the effect of these false-negatives on the risk estimate is 
presumably low. It is therefore likely that the specificity of IgAN in the current study is 
high, but that the sensitivity is lower, with implications for external validity (see section 
6.2.3). The incidence rate in this study (25 PMP and year in the CD group, 8 PMP in 
reference individuals) was slightly lower than reported by other European studies (15-
40 PMP and year), further supporting this notion.    
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6.1.2.4.5 Misclassification- diagnosis of CD in the ABIS study (Study IV) 
 
Children from the ABIS cohort were not screened for CD, thus all reported cases of CD 
represent diagnosed CD (VA, CD consistent symptoms and positive CD serology). The 
occurrence of false-negatives among reference individuals is thus likely but presumably 
with little effect on the estimates.  
 
6.1.2.5 Confounding 
 
Confounding is often described as a mixing of effects. A confounder is a factor that is 
associated with the exposure of interest, and is an independent risk factor for the 
outcome. Importantly, a confounder is not on the causal pathway between the outcome 
and the exposure. When confounding is present, the true association between the 
exposure and outcome is blurred due to the effect of the confounding factor. The effects 
of a confounder can be handled in several ways, for example by matching, 
randomization, restriction, stratification and in adjusted regression models218. These 
methods require that potential confounding factors are considered in the study design, 
so that data on the confounding variable may be collected for participants.  
 
Different methods of handling confounding have been used in this thesis. In studies I-
III, reference individuals where matched for age at CD diagnosis, sex, calendar period 
at diagnosis of CD and county. In the Cox regression model, analyses were performed 
stratum wise and in the case-control studies, we used conditional logistic regression, 
thus accounting for confounding effects due to these variables. In studies I-III, we 
adjusted for confounding factors such as diabetes mellitus, country of birth (Nordic vs 
non-Nordic) (studies I-III), liver disease (III), educational level (studies II-III), and 
socioeconomic position (study I) by inclusion in the regression model. Additionally, we 
performed analyses stratified by age at CD diagnosis (study I), length of follow up 
(studies II-III), sex (studies I-III), and age and calendar period at first intestinal biopsy 
(studies II-III). To adjust for the potentially confounding effect of any previous renal 
disease, we used a model which we restricted to individuals without previous renal 
disease (study III).  Stratification (univariate and bivariate analyses) and inclusion in 
regression models (main analysis) were methods used to assess potential confounding 
effects in study IV.  
 
A common confounder in epidemiological studies is smoking. We did not have any 
data on smoking in our studies. Since smoking is a risk factor for VTE and ESRD, but 
has no association226  or a negative association227 with CD, it is unlikely to explain our 
findings in study I and II. A recent study shows no association between CD and 
educational level, however CD was slightly less common among individuals with low 
socioeconomic position228. We adjusted for socioeconomic position in study I, and for 
educational level in studies II-III. The protective effect of smoking and low 
socioeconomic position may both reflect an increased risk of undiagnosed CD due to 
different health-care seeking behavior among individuals with a low socioeconomic 
position.  
 
6.1.2.6 Random error  
 
Null results as well as positive findings may be due to chance. A random error reflects 
the power of a study, and will be minimized as the size of the population under study 
increases. The role of chance is roughly estimated by confidence intervals and p-values. 
A large sample size will result in a narrow confidence interval and a small p-value; we 
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say that the precision is high. It is important to distinguish between precision and 
validity. A high degree of precision does not imply a high degree of validity. When 
assessing an association between exposure and outcome, Hill’s criteria of causal 
associations (see Table 8) should be considered irrespective of sample size and 
precision218, bearing in mind that association is not equal to causation.  
 
In studies I-II, exposure and outcome data were based on national registers allowing a 
large sample size and high precision. In study III, the outcome of study (IgAN) was 
rare yielding wider confidence intervals, non-significant results in stratified analyses 
and restricting the interpretation of stratified analyses due to strata with lack of positive 
events. Furthermore, the large number of subanalyses increases the risk of chance 
findings.  
 
Table 8. Hill's criteria for causality. 1. Strength of the association 2. Consistency upon repeated observation  3. Specificity of the association 4. Temporality (cause preceding effect) 5. Dose‐response or exposure‐response effect 6. Scientific plausibility of the association 7. Coherence with available knowledge  8. Experimental evidence 9. Analogy 
 
 
6.1.3 External validity 
The concept of external validity is defined as the extent to which the findings of the 
study are generalizable to other groups outside the population included in the study.  
 
A threat to the external validity of study I is the limitation of CD to inpatients. As 
previously discussed, inpatient care was more common during the majority of the study 
period than it is today, and children (the majority of individuals in this study) more 
often require inpatient care during investigation for CD. Even today, some children 
may be hospitalized and require general anaesthesia for small intestinal biopsy 
acquirement. The population in study I is thus likely a mix of individuals admitted for 
therapeutic or diagnostic reasons, or for concomitant disease. The results of this study 
are not generalizable to individuals with potential or asymptomatic CD.  
 
In studies II and III, external validity in diagnosed CD is high since we are confident 
that we have captured the vast majority of Swedish individuals diagnosed with CD 
during the study period. Our confidence in the data is further supported by findings of 
high specificity of CD in VA, and findings of high frequencies of small intestinal 
biopsies obtained by Swedish physicians when diagnosing CD120. Again, since 
individuals with CD may be undiagnosed, these studies reveal no information regarding 
the risk of ESRD or IgAN in undiagnosed CD. Age at CD diagnosis could possibly be 
a proxy for the length of exposure of undiagnosed CD. In these studies, analyses 
stratified for age at CD diagnosis revealed no difference in risk of outcome according to 
age at CD diagnosis.  
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A potential issue for concern regarding generalizability of the studies in this thesis is 
the restriction to a Swedish population. Potential demographic differences, e.g. 
environmental exposures and genetics should be taken into consideration when 
extrapolating our findings to populations in other parts of the world.   
 
 
6.2 FINDINGS AND IMPLICATIONS 
6.2.1 Study I 
VTE is a common source of morbidity and mortality169. We hypothesized that 
individuals with CD would suffer increased risk of VTE, mainly due to the effects of 
chronic inflammation with hyperhomocysteinemia182. We found a modestly increased 
risk of VTE in adults diagnosed with CD.  This association may in part be explained by 
surveillance bias.  
 
We had no data on the adherence to a GFD in this study, nor data on follow-up 
biopsies. We can therefore not exclude that among the subjects under study, the risk of 
VTE may be higher in individuals with poor adherence and likely a higher degree of 
persisting intestinal inflammation.  
 
Our results are in contrast with the previous study by Miehsler et al. that found no 
association between CD and VTE. That study was, however, smaller (CD n= 207), 
originally designed to study IBD and included only a small number of patients170. A 
more recent, Danish register based case-control study examined the occurrence of CD 
in individuals with a record of VTE. Although no association was found (adjusted OR, 
1.0; 95% CI 0.8-1.4), individuals with CD diagnosed within 90 days before VTE 
diagnosis were at increased VTE risk (adjusted OR, 9.2; 95% CI 1.4-61)229. Important 
differences between that study and ours is the inclusion of individuals with dermatitis 
herpetiformis in the CD group, inclusion of outpatients with CD, and adjustment for 
pregnancy or infection within 3 months prior to VTE diagnosis.  
 
In conclusion, our study in conjunction with previous studies provide evidence that 
diagnosed CD is not a major risk factor for VTE. 
 
6.2.2 Study II 
Individuals with CD suffered a three-fold increased risk of ESRD. This risk increase 
was seen irrespective of age at CD diagnosis, sex, calendar period, and length of 
follow-up from CD diagnosis. Our results are coherent with previous research implying 
an association between CD and renal disease196 161, 195. These studies were however 
limited to in-patients161, 195, 196. Our results remained statistically significant after 
adjusting for diabetes mellitus type 1, excluding individuals with any prior renal 
disease, and excluding the first year of follow-up to minimize surveillance bias. When 
we stratified the analysis according to modality of treatment, we found an increased 
risk of dialysis but not renal transplantation in individuals with CD.  
 
One must bear in mind the differences between absolute and relative risks when 
discussing the findings of this study. ESRD is a severe diagnosis with vast 
consequences in the lives of those affected. However, it is a rare disorder, and although 
we found a three-fold increased risk of ESRD in individuals with CD, the absolute risk 
of ESRD in CD was low (0.3%).  
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Biological mechanisms causing the association between CD and ESRD have yet to be 
explained, however shared disease characteristics such as increased gut permeability190, 
191 and impaired oral tolerance192, 193 have been suggested.  
 
This study has a few important limitations. We had no data on adherence to a gluten-
free diet. We cannot exclude that increased inflammatory activity due to poor 
adherence could contribute to higher risk estimates. Furthermore, we had no data on 
smoking. Although smoking is a risk factor for ESRD, it has no association226  or a 
negative association227 with CD, and is unlikely to explain our findings.  
 
Renal replacement therapy is associated with low quality of life, high mortality and 
morbidity, and high costs186. The potential gains, for the patient and for the society, of 
preventing ESRD or delaying the need for renal replacement therapy in individuals 
with chronic renal disease are substantial. An important strength of the current study is 
that we included all individuals with diagnosed CD in Sweden. If others replicate our 
findings, clinical guidelines of CD may need to be altered to include greater awareness 
regarding renal function.  
 
6.2.3 Study III 
We suggest that individuals with CD suffer increased risk of IgAN. The risk was 
restricted to men, and stratified analyses had low power to detect significant risk 
estimates.  
 
Our findings are in line with previous research. It has previously been shown that 
patients with IgAN suffer increased risk of CD195. Although previous studies suggest an 
association between CD and renal disease, they do not provide detailed information on 
specific renal diseases161, 196, 205. Although underlying mechanisms are unknown, the 
study by Collin et al negates association based on HLA genotype195.  
 
An important strength of this study is the classification of disease and exposure 
according to biopsy reports. Given the wide spectrum of disease presentation in IgAN, 
it is likely that the sensitivity of IgAN in this study is low (even though we presumably 
have included all cases of diagnosed IgAN). Furthermore, IgAN is inseparable from 
Henoch-Schonlein Purpura upon biopsy examination199. We assume that written 
referrals include patient histories and that this is taken into consideration by the 
pathologists when diagnosing IgAN. We know of no validation studies of the IgAN 
diagnosis in Swedish biopsy registers.  
 
We know of no previous study investigating the risk of biopsy-verified IgAN in biopsy-
verified CD. In conclusion, men with CD suffer increased risk of IgAN. This may 
contribute to the observed association between CD and ESRD.  
 
6.2.4 Study IV 
Although we hypothesized that infection at time of gluten introduction would increase 
the risk of future CD, we found no such association after adjusting for age at gluten 
introduction, age at end of breastfeeding, and age at infection. Nor did we see an 
association between age at gluten introduction, or age at end of breastfeeding and risk 
of future CD. This contradicts previous research, that has found increased risk for CD 
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among children with short breastfeeding duration < 2 months88, < 90 days84 or < 30 
days87, although results have been inconsistent89, 90.  
 
We did not have any data on clinically diagnosed infectious disease or specific 
pathogens but only parent-reported infectious disease. This is a disadvantage, and may 
lead to misclassification of exposure. The lack of detail regarding aetiologies may blur 
existing associations between certain pathogens and risk of future CD. Furthermore, we 
have no data on gluten dosage, which might impact the risk of an early CD diagnosis.  
 
An important feature of the current study is it’s prospective design. Additionally, 
children included in the ABIS study were born in 1997-1999, that is after the Swedish 
epidemic of CD, and after the introduction of new infant dietary guidelines by the 
Swedish Pediatric Society (see Figure 3). More than one half of all children were 
breastfed for > 9 months. Gluten was introduced in months 5-6 in the majority of 
children. No children with CD were exposed to gluten before the age of 2 months. The 
changes in infant feeding pattern seen in Sweden the past decades58 may explain why 
we did not find an independent effect of breastfeeding nor age at gluten introduction on 
the risk of future CD, whereas previous studies did85, 86. We conclude that given current 
dietary guidelines, these environmental factors are no major risk factors for CD.  
 
 
6.3 IMPLICATIONS FOR FUTURE RESEARCH 
Future research should consider: 
 
- The potential effects of GFD adherence on the occurrence of subsequent 
complications. 
- Increased knowledge regarding mechanisms and combinations of risk factors 
that lead to complications. Such awareness could possibly allow for 
identification of individuals at risk. In a visionary future, where health care is 
increasingly personalized, individual parameters may aid in determining 
individual risk-profiles and disease management strategies.  
- Further studies of individuals with ESRD, to compare disease characteristics in 
patients with and without CD. Thereby it would be feasible to determine 
possible unique features in terms of survival, benefit from various 
cardiovascular treatments, and parameters such as anemia and bone metabolism 
in patients with CD and ESRD.  
- Validating the IgAN diagnosis in Swedish biopsy registers.  
- Specify pathogens when assessing the role of infection in CD pathogenesis.  
- Including longer follow-up periods in studies of infant feeding patterns and 
future CD, to determine whether these factors merely affect induction time, 
truly protect against CD or have no association with CD.   
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7 CONCLUSIONS 
I) CD is associated with a modestly increased risk of future VTE. This risk increase is 
restricted to individuals diagnosed with CD in adulthood, and is likely the result of a 
combination of chronic inflammation and surveillance bias.  
 
II) Individuals with CD suffer a three-fold increased risk of future ESRD, independent 
of age at CD diagnosis. We suggest awareness regarding renal function in individuals 
with CD.  
 
III) Individuals with CD suffer increased risk of IgAN. This risk increase was restricted 
to men and we had low power to conduct stratified analyses. IgAN may be an 
underlying contributor to the increased risk of ESRD seen in CD.  
 
IV) Children with infection at time of gluten introduction suffer no increased risk of 
future CD. Contrary to previous research, we did not find an independent effect of 
breastfeeding duration nor age at gluten introduction on the risk of future CD.  
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8 SAMMANFATTNING PÅ SVENSKA 
Celiaki (glutenintolerans) är en sjukdom som drabbar cirka 1% av befolkningen i 
västerländska populationer. Hos individer med celiaki leder intag av vete, råg eller korn 
till en immunmedierad inflammation i tunntarmen och destruktion av tarmluddet. 
Celiaki kan debutera när som helst i livet. För att drabbas av sjukdomen krävs att man 
har generna HLA-DQ2 eller HLA-DQ8. Eftersom denna genotyp är vanlig (återfinnes 
hos cirka 1/3 av befolkningen) så kan den inte förklara varför vissa individer får celiaki. 
Mekanismerna bakom sjukdomsutvecklingen i celiaki är okända, dock har tidigare 
forskning pekat på att amning kan skydda mot celiaki, och att viss infektionssjukdom är 
vanligare hos de som drabbas av celiaki. Individer med celiaki löper ökad risk för ett 
antal andra sjukdomar, exempelvis diabetes mellitus typ 1, thyroideasjukdom och 
depression.  
 
Syftet med denna avhandling var att identifiera tillstånd och komplikationer som är 
kopplade till celiaki, för att bättre förstå sjukdomen och kanske kunna förebygga 
komplikationer, samt eventuellt identifiera grupper med förhöjd risk för celiaki. Ett 
annat syfte var att undersöka huruvida risken för celiaki påverkas hos barn som lider av 
infektion samtidigt som de för första gången i sitt liv äter mat innehållande gluten.  
 
I studie I undersökte vi risken för venös tromboembolism (VTE; lungemboli eller djup 
ventrombos) hos individer med celiaki. Tidigare forskning har föreslagit att den 
kroniska inflammation som föreligger vid celiaki leder till hyperhomocysteinemi, vilket 
i sin tur är kopplat till förhöjd risk för VTE. Vi identifierade 14,207 individer med 
celiaki i det svenska slutenvårdsregistret, och 69,048 matchade kontroller i 
befolkningsregistret. Genom Cox regression fann vi att individer med celiaki löper en 
lätt förhöjd risk för VTE (Hazard ratio, HR, 1.86; 95% konfidensintervall, KI, 1.54-
2.24). Sambandet mellan celiaki och VTE sågs endast hos individer som fått sin 
celiakidiagnos i vuxen ålder (>15 år). Vi tror att denna överrisk beror på kronisk 
inflammation, men också till viss del på grund av ett skevt urval då vi endast studerade 
patienter med celiaki som slutenvårdsdiagnos.  
 
Terminal njursvikt innebär ett behov av njurtransplantation eller kontinuerlig 
dialysbehandling. Tidigare studier har föreslagit en koppling mellan celiaki och 
terminal njursvikt, men har varit baserade på celiaki diagnosticerad i slutenvård vilket 
ger risk för en skev bild. I studie II identifierade vi svenskar med celiaki genom deras 
tunntarmsbiopsi. Samtliga patologikliniker i Sverige kontaktades och rapporterade 
individer med celiaki från 1969-2008. 29,050 individer med celiaki och utan njursvikt 
vid studiens start identifierades, liksom via befolkningsregistret 144,363 matchade 
kontroller. Terminal njursvikt identifierades initialt genom koppling till sluten- och 
öppenvårdsregister samt senare även till Svenskt njurregister. Vi fann en nästan tre 
gånger förhöjd risk för terminal njursvikt hos individer med celiaki (HR, 2.87; 95% KI 
2.22-3.71). Risken var något högre när vi begränsade utfallet till individer med 
njursviktsdiagnos i ett patientregister och i Svenskt njurregister.  
 
IgA nefropati är en njursjukdom som karaktäriseras av njurinflammation och 
depositioner av IgA antikroppar i njurens mesangium. Den drabbar cirka 15-40 
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personer per miljon människor och år och leder hos 15-50% av fallen till terminal 
njursvikt. I studie III undersökte vi risken för IgA nefropati hos personer med celiaki. 
Detta då en tidigare studie funnit en ökad risk för celiaki hos patienter med IgA 
nefropati, men även för att bättre förstå vad som orsakar kopplingen mellan celiaki och 
njursjukdom. Vi utgick ifrån samma celiakicohort och referenspopulation som i studie 
II. För att identifiera dem som utvecklat IgA nefropati kontaktade vi de fyra 
patologikliniker som diagnosticerar njurbiopsier. Genom datoriserade sökningar fann vi 
4,069 individer med IgA nefropatidiagnos i svenska biopsiregister. Individer med 
celiaki löper en förhöjd risk för IgA nefropati (HR, 3.03; 95% KI 1.22-7.56). 
Riskökningen sågs endast hos män.  
 
I studie IV undersökte vi mekanismerna bakom sjukdomsutveckling i celiaki. Vår 
hypotes var att en infektion under den känsliga tidpunkt i livet då barn för första gången 
inkluderar gluten i kosten leder till ökad risk för celiaki, förslagsvis på grund av felaktig 
aktivering av immunsystemet. Detta undersökte vi med hjälp av data från ABIS studien 
(Alla Barn i Sydöstra Sverige); en studie som genomfördes 1997-1999 för att 
undersöka miljöfaktorer relaterade till immunmedierad sjukdom. Föräldrar till barn 
som föddes under studieperioden erbjöds delta. Studiedeltagare erhöll en första enkät 
på BB, och ombads sedan föra en dagbok över barnets sjukdomar och födointag under 
första året. Av de 21,700 barn som föddes, valdes föräldrarna till 17,055 barn att delta. 
Slutligen erhöll vi komplett dagboksdata (med information om amningslängd samt 
datum för glutenintroduktion) för 9,408 barn varav 44 utvecklade celiaki. Information 
om celiakidiagnos hämtades från barnklinikerna i området. Hos dessa barn förekom 
42,826 föräldrarapporterade infektionsepisoder. När vi justerade för amningslängd och 
ålder vid infektion och glutenintroduktion, fann vi att infektion vid tiden för 
glutenintroduktion inte är kopplat till en förhöjd risk för framtida celiaki (HR, 1.8; 95% 
KI 0.9-3.6). Gastroenterit vid glutenintroduktion var ej heller kopplat till risk för 
framtida celiaki (HR, 2.6; 95% KI 0.2-30.8). En nackdel med denna studie är att vi 
endast kunde följa barnen fram till och med 30 juni 2006. Det är därför möjligt att de 
parametrar vi studerade endast förskjuter symptomdebut längre fram i livet. Vidare är 
det möjligt att specifika patogener, exempelvis rotavirus, påverkar celiakirisken, vilket 
vi ej kan utesluta i denna studie.  
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